ViewRay (VRAYQ) 10-K 25 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 15, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-37725
Entity Registrant Name	ViewRay, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	42-1777485
Entity Address, Address Line One	2 Thermo Fisher Way
Entity Address, City or Town	Oakwood Village
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44146
City Area Code	440
Local Phone Number	703-3210
Title of 12(b) Security	Common Stock, par value $0.01
Trading Symbol	VRAY
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 1,058,915,946
Entity Common Stock, Shares Outstanding		179,404,696
Documents Incorporated by Reference	Portions of the Registrant’s definitive proxy statement to be delivered to stockholders in connection with the Annual Meeting of Shareholders to be held in 2022 are incorporated by reference in Part III of this Form 10-K where indicated.
Entity Central Index Key	0001597313
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Auditor Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Denver, CO
Auditor Firm ID	34

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 218,348	$ 156,720
Accounts receivable	21,659	11,769
Inventory, net of allowance of $3,071 and $2,286, respectively	29,617	46,641
Deposits on purchased inventory	4,778	2,084
Deferred cost of revenue	3,342	1,954
Prepaid expenses and other current assets	5,803	5,257
Total current assets	283,547	224,425
Property and equipment, net	20,242	24,062
Restricted cash	1,460	1,460
Intangible assets, net	44	50
Right-of-use assets	9,661	10,129
Other assets	6,853	1,426
TOTAL ASSETS	321,807	261,552
Current liabilities:
Accounts payable	9,199	9,984
Accrued liabilities	26,555	19,281
Customer deposits	20,784	15,463
Operating lease liability, current	2,561	2,089
Current portion of long-term debt	3,222	0
Deferred revenue, current portion	13,920	10,094
Total current liabilities	76,241	56,911
Deferred revenue, net of current portion	4,232	2,572
Long-term debt	54,031	56,940
Warrant liability	6,795	4,864
Operating lease liability, noncurrent	8,066	9,043
Other long-term liabilities	2,647	956
TOTAL LIABILITIES	152,012	131,286
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, par value $0.01 per share; 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020	0	0
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at December 31, 2021 and 2020; 179,206,456 and 148,615,351 shares issued and outstanding at December 31, 2021 and 2020	1,782	1,476
Additional paid-in capital	905,145	755,874
Accumulated deficit	(737,132)	(627,084)
TOTAL STOCKHOLDERS’ EQUITY	169,795	130,266
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 321,807	$ 261,552

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Inventory, allowance	$ 3,071	$ 2,286
Stockholders’ equity:
Preferred stock, par value per share (USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value per share (USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	179,206,456	148,615,351
Common stock, shares outstanding (in shares)	179,206,456	148,615,351

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 70,119	$ 57,017	$ 87,782
Cost of revenue:
Total cost of revenue	69,784	61,076	93,260
Gross profit (loss)	335	(4,059)	(5,478)
Operating expenses:
Research and development	31,849	25,008	23,794
Selling and marketing	16,044	15,181	25,806
General and administrative	56,091	61,729	65,717
Total operating expenses	103,984	101,918	115,317
Loss from operations	(103,649)	(105,977)	(120,795)
Interest income	13	791	1,721
Interest expense	(4,241)	(3,307)	(4,327)
Other income (expense), net	(2,171)	585	3,202
Loss before provision for income taxes	(110,048)	(107,908)	(120,199)
Provision for income taxes	0	0	0
Net loss attributable to common stockholders, basic and diluted	$ (110,048)	$ (107,908)	$ (120,199)
Net loss per share, basic (USD per share)	$ (0.67)	$ (0.73)	$ (1.18)
Net loss per share, diluted (USD per share)	$ (0.67)	$ (0.73)	$ (1.18)
Weighted-average common shares used in computing net loss per share, diluted (in shares)	164,521,064	147,895,561	102,001,954
Weighted-average common shares used in computing net loss per share, basic (in shares)	164,521,064	147,895,561	102,001,954
Product
Revenue:
Total revenue	$ 51,865	$ 42,742	$ 79,504
Cost of revenue:
Total cost of revenue	51,780	49,347	80,446
Service
Revenue:
Total revenue	17,779	13,800	7,803
Cost of revenue:
Total cost of revenue	18,004	11,729	12,814
Distribution rights
Revenue:
Total revenue	$ 475	$ 475	$ 475

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2018		96,332,023
Beginning balance at Dec. 31, 2018	$ 167,309	$ 952	$ 565,334	$ (398,977)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from option exercises (in shares)		2,219,251
Issuance of common stock from option exercises	9,641	$ 23	9,618
Issuance of common stock from releases of restricted stock units (in shares)		393,722
Issuance of common stock from releases of restricted stock units	0	$ 4	(4)
Tax withholding paid on behalf of employees for stock-based awards	(2,410)		(2,410)
Stock-based compensation	19,444		19,444
Issuance of common stock upon public offering, net of offering costs (in shares)		47,782,500
Issuance of common stock upon public offering, net of offering costs	138,413	$ 478	137,935
Issuance of common stock from warrant exercises (in shares)		464,199
Issuance of common stock from warrant exercises	0	$ 5	(5)
Reclassification of warrant liability to additional paid-in capital upon warrant exercises	3,976		3,976
Net loss	(120,199)			(120,199)
Ending balance (in shares) at Dec. 31, 2019		147,191,695
Ending balance at Dec. 31, 2019	216,174	$ 1,462	733,888	(519,176)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from option exercises (in shares)		20,579
Issuance of common stock from option exercises	15		15
Issuance of common stock from releases of restricted stock units (in shares)		1,214,786
Issuance of common stock from releases of restricted stock units	0	$ 12	(12)
Tax withholding paid on behalf of employees for stock-based awards	(1,376)		(1,376)
Stock-based compensation	22,805		22,805
Issuance of common stock from employee stock purchase plan (in shares)		188,291
Issuance of common stock from employee stock purchase plan	365	$ 2	363
Write-down of offering costs related to previous issuance of common stock upon public offering	191		191
Net loss	(107,908)			(107,908)
Ending balance (in shares) at Dec. 31, 2020		148,615,351
Ending balance at Dec. 31, 2020	$ 130,266	$ 1,476	755,874	(627,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from option exercises (in shares)	156,199	156,199
Issuance of common stock from option exercises	$ 775	$ 3	772
Issuance of common stock from releases of restricted stock units (in shares)		4,015,380
Issuance of common stock from releases of restricted stock units	0	$ 40	(40)
Tax withholding paid on behalf of employees for stock-based awards	(4,600)		(4,600)
Stock-based compensation	23,871		23,871
Issuance of common stock upon public offering, net of offering costs (in shares)		26,231,500
Issuance of common stock upon public offering, net of offering costs	128,626	$ 262	128,364
Issuance of common stock from employee stock purchase plan (in shares)		142,974
Issuance of common stock from employee stock purchase plan	550	$ 1	549
Fair value of warrants upon exercise	352		352
Issuance of common stock from warrant exercises (in shares)		44,287
Issuance of common stock from warrant exercise (cash exercise) (in shares)		765
Issuance of common stock from warrant exercise (cash exercise)	3		3
Net loss	(110,048)			(110,048)
Ending balance (in shares) at Dec. 31, 2021		179,206,456
Ending balance at Dec. 31, 2021	$ 169,795	$ 1,782	$ 905,145	$ (737,132)

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Offering cost	$ 11,146	$ 9,334

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (110,048,000)	$ (107,908,000)	$ (120,199,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,984,000	6,419,000	4,655,000
Stock-based compensation	23,871,000	22,805,000	19,445,000
Accretion on asset retirement obligation	105,000	63,000	43,000
Change in fair value of warrant liability	2,284,000	(509,000)	(2,496,000)
Loss on disposal of property and equipment	0	139,000	3,000
Inventory lower of cost and net realizable value adjustment	883,000	150,000	0
Amortization of debt discount and interest accrual	919,000	729,000	703,000
Product upgrade reserve	1,000,000	(2,294,000)	3,794,000
Changes in operating assets and liabilities:
Accounts receivable	(9,890,000)	5,048,000	20,050,000
Inventory	15,565,000	8,240,000	(5,951,000)
Deposits on purchased inventory	(2,694,000)	4,373,000	1,685,000
Deferred cost of revenue	(1,388,000)	(186,000)	1,755,000
Prepaid expenses and other assets	(5,550,000)	(1,356,000)	2,963,000
Accounts payable	(746,000)	(3,352,000)	2,759,000
Accrued expenses and other long-term liabilities	6,807,000	(292,000)	6,995,000
Customer deposits and deferred revenue	10,807,000	4,457,000	(15,771,000)
Net cash used in operating activities	(62,091,000)	(63,474,000)	(79,567,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,559,000)	(6,183,000)	(7,760,000)
Purchase of intangible and other assets	0	0	(57,000)
Net cash used in investing activities	(1,559,000)	(6,183,000)	(7,817,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from term loan modification	0	2,000,000	0
Payment of debt issuance costs	0	(815,000)	(168,000)
Proceeds from common stock public offerings, gross	137,884,000	0	149,559,000
Payment of offering costs related to common stock public offerings	(9,334,000)	(539,000)	(10,416,000)
Proceeds from employee stock purchase plan	550,000	365,000	0
Proceeds from the exercise of stock options	775,000	15,000	9,641,000
Proceeds from the exercise of warrants	3,000	0	0
Payments for taxes related to net share settlement of equity awards	(4,600,000)	(1,376,000)	(2,410,000)
Net cash provided by (used in) financing activities	125,278,000	(350,000)	146,206,000
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	61,628,000	(70,007,000)	58,822,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF PERIOD	158,180,000	228,187,000	169,365,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF PERIOD	219,808,000	158,180,000	228,187,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	3,323,000	3,262,000	3,954,000
Cash paid for taxes	0	43,000	19,000
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of common stock warrants reclassed from liability to additional paid-in capital upon exercise	352,000	0	3,975,000
Right-of-use assets obtained in exchange for new operating lease liabilities	1,693,000	643,000	1,647,000
Transfer of property and equipment from inventory	576,000	1,698,000	4,897,000
Purchase of property and equipment in accounts payable and accrued expenses	82,000	59,000	657,000
Offering costs included in accounts payable and accrued expenses	$ 25,000	$ 460,000	$ 730,000

Background and Organization

Background and Organization	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Organization	Background and Organization ViewRay, Inc. ("ViewRay" or the "Company"), and its wholly-owned subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, an MR Image-Guided radiation therapy system to simultaneously image and treat cancer patients. Since inception, ViewRay Technologies, Inc. has devoted substantially all of its efforts towards research and development, initial selling and marketing activities, raising capital and the manufacturing, shipment and installation of MRIdian systems. In May 2012, ViewRay Technologies, Inc. was granted clearance from the U.S. Food and Drug Administration (“FDA”), to sell MRIdian with Cobalt-60. In November 2013, ViewRay Technologies, Inc. received its first clinical acceptance of a MRIdian with Cobalt-60 at a customer site, and the first patient was treated with that system in January 2014. ViewRay Technologies, Inc. has had the right to affix the CE mark to MRIdian with Cobalt-60 in the European Economic Area ("EEA") since November 2014. In September 2016, the Company received the rights to affix the CE mark to MRIdian Linac, and in February 2017, the Company received 510(k) clearance from the FDA to market MRIdian Linac. In February 2019, the Company received 510(k) clearance from the FDA for advancements in MRI, 8 frames per second cine, and Functional imaging (T1/T2/DWI) and High-Speed MLC. In December 2019, we received the CE mark for these advancements in the EEA. In December 2021, the Company received 510(k) clearance from the FDA on its recent submission for new MRIdian features ("MRIdian A3i TM ) focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchanges Commission (the "SEC"). The consolidated financial statements include the accounts of ViewRay, Inc. and its wholly-owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allocation of revenue to multiple performance obligations within an arrangement, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards and warrant liability, and valuation allowances against deferred tax assets. Actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company deposits its cash primarily in checking and money market accounts. The carrying amounts of the Company’s cash equivalents approximate their fair values due to their short maturities. Restricted Cash At December 31, 2021 and 2020, the Company had an aggregate of $1.5 million of outstanding letters of credit related to its operating leases and its contractual obligations with distributors and customers. The letters of credit are collateralized by a restricted cash deposit account, which is presented as part of noncurrent assets on the balance sheets because the Company is not certain when the restriction will be lifted on the collateralized letters of credit. At December 31, 2021 and 2020, no amounts were drawn on the letters of credit. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in checking and money market accounts with various financial institutions. At times, cash balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company performs periodic credit evaluations of its customers’ financial condition and generally requires deposits from its customers. The Company’s accounts receivable were derived from billings to customers. The Company’s customers representing greater than 10% of accounts receivable or revenue for the periods presented were as follows: Revenue Accounts Receivables Year Ended December 31, December 31, Customers 2021 2020 2019 2021 2020 Customer A 11 % 12 % 14 % 28 % Customer B 16 % Customer C 16 % Customer D 15 % Customer E 19 % Customer F 11 % 30 % Customer G 10 % 20 % Customer H 25 % The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of MRIdian, competition from substitute products and larger companies, protection of proprietary technology, ability to maintain distributor relationships and dependence on key individuals. Furthermore, new products to be developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. The Company relies on a concentrated number of suppliers to manufacture essentially all of the components used in MRIdian. The Company’s suppliers may encounter problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA’s Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede our ability to meet demand. Accounts Receivables and Allowance for Credit Losses Accounts receivable are recorded at the invoiced amount, net of any allowance for credit losses, and do not bear interest. The allowance for credit losses, if any, is based on the assessment of the collectability of customer accounts. There was no allowance for credit losses recorded at December 31, 2021 and 2020. Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, restricted cash, prepaid expenses and other current assets, accounts payable, accrued liabilities, warrant liability and long-term debt. Cash equivalents are stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities current portion of long-term debt are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. The warrant liability is carried at fair value. The carrying amount of the Company’s long-term debt approximates its fair value as the stated interest rate approximates market rates currently available to the Company. Inventory and Deposits on Purchased Inventory Inventory consists of purchased components for assembling MRIdian systems and other direct and indirect costs associated with MRIdian system installation. Inventory is stated at the lower of cost or net realizable value. All inventories expected to be placed in service during the normal operating cycle of the Company for the delivery and assembly of MRIdian systems, including items expected to be on hand for more than one year, are classified as current assets. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. The Company reduces the carrying value of its inventory for the difference between cost and net realizable value and records a charge to cost of product revenues. The Company recorded an inventory lower of cost and net realizable value adjustment of $0.9 million and $0.2 million during the years ended December 31, 2021 and 2020, respectively. There was no lower of cost and net realizable value adjustment during the year ended December 31, 2019. The Company records inventory items which have been paid for but not yet received and for which title has not yet transferred to the Company as deposits on purchased inventory. Deposits on purchased inventory are included within current assets as the related inventory items are expected to be received and used in MRIdian systems within the Company’s normal operating cycle. The Company assesses the recoverability of deposits on purchased inventory based on credit assessments of the vendors and their history supplying these assets. At December 31, 2021, the Company did not have any instances whereby deposits for purchased inventory were written off or the purchased inventory was not delivered. Shipping and Handling Costs Shipping and handling costs for product shipments to customers are included in cost of product revenue. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of product revenue. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed over the estimated useful lives, ranging from two Depreciation and amortization periods for property and equipment are as follows: Property and Equipment Estimated Useful Life Prototype 2 - 10 years Machinery and equipment 3 - 15 years Furniture and fixture 5 - 10 years Software 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities, current and noncurrent, on our consolidated balance sheets. We currently do not have any finance lease arrangements. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date of the lease in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include an option to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Asset Retirement Obligations In connection with two lease agreements and subsequent amendments, the Company has a legal obligation to remove long-lived assets constructed on the leased properties and to restore the leased properties to their original condition. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The fair value is measured based upon the present value of the expected future payments at inception and remeasured upon the extension of the respective lease agreement. The liability is accreted to its present value each period and the capitalized cost is depreciated over the remaining lease term. Accretion expense is calculated by applying the effective interest rate to the carrying amount of the liability at the beginning of each period. The effective interest rate is the credit-adjusted risk-free rate applied when the liability was initially measured at inception and remeasured upon the lease extension, when applicable. At December 31, 2021, the Company had outstanding asset retirement obligations of $1.0 million, which was included in other long-term liabilities in the accompanying consolidated balance sheets. For the years ended December 31, 2021, 2020 and 2019, the Company recognized accretion expenses of $105 thousand, $63 thousand and $43 thousand, respectively in the accompanying statements of operations and comprehensive loss. Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived assets, including equipment, leasehold improvements, software and intangible assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest charge) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There was no impairment loss recognized during the years ended December 31, 2021, 2020 and 2019. Revenue Recognition The Company derives revenues primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. The Company accounts for revenue contracts with customers by applying the requirements of ASC 606, Revenues from Contracts with Customers, which includes the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. In all sales arrangements, revenues are recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. For sales of MRIdian systems, beginning in the second quarter of 2019, the Company determined that the MRIdian system and installation of the MRIdian system, which had previously been one performance obligation, are now two performance obligations as they are capable of being distinct and are distinct within the context of the system contracts. This change occurred due primarily to changes in facts and circumstances, whereby there are now readily available resources outside the Company that can perform the system installations. For sales of the related support and maintenance services, a time-elapsed method is used to measure progress toward complete satisfaction of performance obligations and service revenue is recognized ratably over the service contract term, which is typically 12 months. Additional details regarding revenue recognition are included in Note 7 – Revenue . Research and Development Costs Expenditures, including payroll, contractor expenses and supplies, for research and development of products and manufacturing processes are expensed as incurred. Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is completed concurrent with the establishment of technological feasibility. Stock-Based Compensation Stock-based compensation expense for all stock-based payment awards granted is based on the grant date fair value. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions (see Note 13). The fair value of the portion of the award that is ultimately expected to vest is recognized as compensation expense over the awards’ requisite service periods in the consolidated statements of operations and comprehensive loss. The Company records the value of stock-based compensation to expense straight-line over the vesting period. Deferred Commissions Deferred commissions are the direct and incremental costs directly associated with the MRIdian system contracts with customers, which primarily consist of sales commissions to our direct sales force. The commissions are deferred and expensed in proportion to the revenue recognized upon the acceptance of the MRIdian system. At December 31, 2021 and 2020, the Company had $3.3 million and $2.4 million, respectively, in deferred commissions recorded as part of prepaid expenses and other current assets on the consolidated balance sheets. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more-likely-than not that the deferred tax assets will not be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its net deferred tax assets. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more likely than not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. It is the Company’s policy to include any penalties and interest related to income taxes in its income tax provision; however, the Company currently has no penalties or interest related to income taxes. The earliest year that the Company is subject to examination is the year ended December 31, 2004. Warrant Liability Certain warrants to purchase common stock provide for cash settlement in the event of a change in control, and are recorded as liabilities on the balance sheets at fair value upon issuance (see Note 12). These warrants are subject to re-measurement to fair value at each balance sheet date. Any changes in fair value are recognized in the consolidated statements of operations and comprehensive loss as other income (expense), net. Upon exercise of the warrants, the related warrant liability will be reclassified to additional paid-in capital. Net Loss per Share The Company’s basic net loss attributable to common stockholders per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Contingently issuable shares are included in the computation of basic net loss per share as of the date that all necessary conditions have been satisfied and issuance of the shares is no longer contingent. The diluted net loss per share is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units and warrants to purchase common stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2020-06, an update to ASC Topic 470, Subtopic - 20, Debt - Debt with Conversion and Other Options, and ASC Topic 815, Subtopic – 40, Derivatives and Hedging - Contracts in Entity's Own Equity. The ASU simplifies the guidance for certain financial instruments with characteristics of liability and equity, including convertible instruments and contracts on an entity’s own equity by reducing the number of accounting models for convertible instruments and amends guidance in ASC Topic 260, Earnings Per Share, relating to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The ASU is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2021, with early adoption permitted for fiscal years that begin after December 15, 2020. The Company does not expect significant changes to our consolidated financial statements and related notes in order to comply with ASU 2020-06. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This ASU changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This ASU was adopted as of January 1, 2021 and there were no significant changes to our consolidated financial statements and related notes.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	Balance Sheet Components Property and Equipment, Net Property and equipment consisted of the following (in thousands): December 31, 2021 2020 Prototype $ 17,730 $ 17,711 Machine and equipment 17,701 17,486 Leasehold improvements 14,088 14,196 Furniture and fixtures 1,295 1,295 Software 1,389 1,389 Construction in progress 1,397 486 Property and equipment, gross 53,600 52,563 Less: accumulated depreciation and amortization (33,358) (28,501) Property and equipment, net $ 20,242 $ 24,062 Depreciation and amortization expense related to property and equipment was $6.0 million, $6.4 million and $4.7 million during the years ended December 31, 2021, 2020 and 2019, respectively. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued payroll and related benefits $ 17,080 $ 12,810 Accrued accounts payable $ 3,740 2,810 Payroll withholding tax, sales and other tax payable $ 1,094 1,398 Accrued legal and accounting $ 230 305 Product upgrade reserve $ 2,500 1,500 Other $ 1,911 458 Total accrued liabilities $ 26,555 $ 19,281 Deferred Revenue Deferred revenue consisted of the following (in thousands): December 31, 2021 2020 Deferred revenue: Product $ 1,322 $ 1,888 Services 15,385 8,857 Distribution rights 1,445 1,921 Total deferred revenue 18,152 12,666 Less: current portion of deferred revenue (13,920) (10,094) Noncurrent portion of deferred revenue $ 4,232 $ 2,572 Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued interest, noncurrent portion $ 704 $ 99 Asset retirement obligation 962 857 Other accrued costs 981 — Total other-long term liabilities $ 2,647 $ 956

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The assets’ or liabilities’ fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments that are carried at fair value mainly consist of Level 3 liabilities. These liabilities that are measured on a recurring basis relate to the 2017 and 2016 Placement Warrants, as described in Note 12. Placement warrant liabilities are valued using the Black-Scholes option-pricing model. Generally, changes in the fair value of the underlying stock, estimated term and volatility would result in a directionally similar impact to the fair value of the warrant (see Note 12). During the year ended December 31, 2021, warrants to purchase 119,420 shares of common stock, were exercised and the aggregate fair value upon exercise of $0.4 million, was reclassified from liabilities to additional paid-in-capital. There were no warrants exercised during the year ended December 31, 2020. The gains and losses from re-measurement of Level 3 financial liabilities are recorded as part of other income (expense), net in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2021, 2020 and 2019, the Company recorded a loss of $2.3 million, and a gain of $0.5 million, and $2.5 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. There have been no transfers between Level 1, Level 2 and Level 3 in any periods presented. The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At December 31, 2021 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 5,030 $ 5,030 2016 Placement Warrants Liability — — 1,765 1,765 Total Warrant Liability $ — $ — $ 6,795 $ 6,795 At December 31, 2020 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 3,675 $ 3,675 2016 Placement Warrants Liability — — 1,189 1,189 Total Warrant Liability $ — $ — $ 4,864 $ 4,864 The following table summarizes the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands): Year Ended December 31, 2021 2020 2019 Fair value, beginning of period $ 4,864 $ 5,373 $ 11,844 Change in fair value of Level 3 financial liabilities 2,284 (509) (2,496) Fair value of 2016 Placement Warrants at exercise (2) — (3,457) Fair value of 2017 Placement Warrants at exercise (351) — (518) Fair value, end of period $ 6,795 $ 4,864 $ 5,373

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	Debt SVB Term Loan In December 2018, the Company entered into a term loan agreement (the "SVB Term Loan") with Silicon Valley Bank, for a principal amount of $56.0 million. The SVB Term Loan has a maturity date of December 1, 2023 and bears interest at a rate of 6.30% per annum to be paid monthly over the term of the loan. Beginning on December 1, 2020 (or June 1, 2021, if the Company achieves a trailing twelve-month revenue of at least a specified amount and elects to apply such later date), the Company would have made thirty-six equal monthly payments of principal (or thirty equal payments, if the Company so elects). In addition, upon repayment of the SVB Term Loan in full, the Company will make a final payment equal to 3.15% of the original aggregate principal amount of the SVB Term Loan. The Company used the proceeds of the SVB Term Loan and cash on hand to repay in full its outstanding obligations under the then outstanding CRG Term Loan and to pay fees and expenses related thereto. The Company accounted for the termination of the CRG Term Loan as a debt extinguishment and recorded a debt extinguishment loss of $2.4 million from the difference between the net carrying amount of debt and the amount paid. The debt extinguishment loss includes $0.3 million in write-off of unamortized debt discount and debt issuance costs associated with the CRG Term Loan. The Company received net proceeds of $55.4 million after related legal and consulting fees totaling $0.6 million. Such fees are accounted for as debt discount and issuance costs and presented as a direct deduction from the carrying amount of debt on the Company’s consolidated balance sheets. Debt discount, issuance costs and the final payment are amortized or accreted as interest expense over the term of the loan using the effective interest method. On December 31, 2019, we entered into the First Amendment (the "First Amendment") to the SVB Term Loan by and among the Company, ViewRay Technologies, Inc. and SVB dated as of December 28, 2018. The First Amendment, among other things, amended the SVB Term Loan to (i) suspend testing of the minimum revenue financial covenant for the fiscal quarter ending December 31, 2019, (ii) provide for the minimum trailing twelve-month revenue thresholds under the minimum revenue financial covenant for periods ending on the last day of fiscal quarters in fiscal years subsequent to 2020 to be determined annually at the greater of (a) a 25% cushion to revenue forecasts provided by the Company to SVB and (b) 10% year-over-year annual growth, unless otherwise agreed, (iii) increase the minimum liquidity ratio financial covenant from 1.50:1.00 to 1.75:1.00 and (iv) increase the prepayment premium from 1.00% to 2.00% for amounts prepaid under the SVB Term Loan for prior to the maturity date thereof, subject to certain exceptions. On October 30, 2020, the Company entered into the Second Amendment (the "Second Amendment") to the SVB Term Loan. The Second Amendment, among other things, amended the SVB Term Loan to (i) increase the term loan agreement principal amount from $56.0 million to $58.0 million, (ii) revise the thirty-six equal monthly payments of principal to begin on November 1, 2022 , (iii) revise the maturity date to October 1, 2025, (iv) decrease the interest rate from a fixed rate of 6.3% to a floating rate of 2.4% above the Prime Rate, (v) increase the final payment from 3.15% of the original aggregate principal amount to 3.7% of the revised aggregate principal amount, (vi) revise the minimum trailing twelve-month revenue thresholds under the minimum revenue financial covenant for periods ending on the last day of fiscal quarters in fiscal years subsequent to 2020 , (vii) decrease the minimum liquidity ratio financial covenant from 1.75:1.00 to 1.70:1.00, (viii) remove the minimum cash balance as a condition of the minimum revenue financial covenant and the minimum liquidity ratio financial covenant, and (ix) increase the prepayment premium from 2.00% to 3.00% for the first 30 months of the term for amounts prepaid under the SVB Term Loan prior to the maturity date thereof, subject to certain exceptions. In connection with the execution of the Second Amendment, the Company agreed to pay the earned portion of the final payment, which equated to $0.8 million. On October 29, 2021, the Company entered into the Third Amendment (the “Third Amendment”) to the SVB Term Loan. The Third Amendment amended the SVB Term Loan to (i) decrease the minimum liquidity ratio financial covenant from 1.70:1.00 to 1.35:1.00, and (ii) increase the prepayment premium from 3.00% to 3.5% for the first 30 months of the term and from 2.00% to 2.50% thereafter for the remaining term, for amounts prepaid under the SVB Term Loan prior to the maturity date thereof, subject to certain exceptions. The SVB Term Loan is secured by substantially all assets of the Company, except that the collateral does not include any intellectual property held by the Company, provided, however, the collateral does include all accounts and proceeds of such intellectual property. The SVB Term Loan contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, dividends and other distributions and transactions with affiliates. The SVB Term Loan also contains financial covenants that require the Company to maintain a minimum cash balance in accounts maintained at Silicon Valley Bank or one of its affiliates or else comply with a liquidity ratio and/or a minimum revenue target. The SVB Term Loan includes standard events of default, including, among other things, subject in certain cases to customary grace periods, thresholds and notice requirements, the Company’s failure to fulfill its obligations under the SVB Term Loan or the occurrence of a material adverse change in the Company's business, operations, or condition (financial or otherwise). In the event of default by the Company under the SVB Term Loan, Silicon Valley Bank would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the SVB Loan, which could harm the Company's financial condition. The Company’s scheduled future payments on the SVB Term Loan at December 31, 2021 are as follows (in thousands): Year Ended December 31, 2022 $ 3,222 2023 19,333 2024 19,333 2025 16,112 Total future principal payments 58,000 Less: unamortized debt discount (747) Carrying value of long-term debt 57,253 Less: current portion (3,222) Long-term portion $ 54,031

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases office space in Oakwood Village, Ohio, Mountain View, California, and Denver, Colorado under non-cancelable operating lease agreements. The Company leases and occupies approximately 19,800 square feet of office space in Oakwood Village, Ohio, which expires in October 2026. The Company entered into an office lease agreement to lease approximately 25,500 square feet of office space located in Mountain View, California, with an expiration date of July 2025. Additionally, the Company entered into a lease agreement to lease additional office space in Mountain View, California of approximately 24,600 square feet, which will expire in December 2025. The Company has the option to extend the term of the lease for a period of up to five years. In March 2021, we entered into a lease agreement to lease approximately 12,800 square feet of office space in Denver, Colorado. The lease commenced on September 1, 2021 and will expire October 31, 2024. In recognition of the right-of-use assets and the related lease liabilities, the option to extend the lease term has not been included as the Company is not reasonably certain that it will exercise any such option. At December 31, 2021, the weighted-average remaining lease term in years is 4.0 years and the weighted-average discount rate used is 7.6%. The Company recognized of $2.8 million, $3.1 million, and $2.9 million lease costs arising from lease transactions for the years December 31, 2021, 2020 and 2019, respectively. During the years ended December 31, 2021, 2020, and 2019, the Company recognized the following cash flow transactions arising from lease transactions (in thousands): For the Year Ended December 31, 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 2,848 $ 3,145 $ 2,451 Right-of-use assets obtained in exchange for new operating lease liabilities 1,693 643 1,647 At December 31, 2021, the future payments and interest expense for the operating leases are as follows (in thousands): Year Ended December 31, Future Payments 2022 $ 3,264 2023 3,357 2024 3,301 2025 2,096 2026 147 Thereafter — Total undiscounted cash flows $ 12,165 Less: imputed interest (1,538) Present value of lease liabilities $ 10,627 Rent expense for operating leases for the year ended December 31, 2019 using the accounting guidance in effect at that time was $1.4 million. Legal Proceedings In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for legal proceedings when it is probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. Class Action Litigation On September 13, 2019, a class action complaint for violation of federal securities laws was filed in U.S. District Court for the Northern District of Ohio against the Company, our chief executive officer, chief scientific officer, and former chief financial officer. On December 19, 2019, the court appointed Plymouth County Retirement Association as the lead plaintiff, and on February 28, 2020 the lead plaintiff filed an amended complaint asserting securities fraud claims against the Company, our chief executive officer, chief operating officer, chief scientific officer, and former chief executive officer and former chief financial officer. Now captioned Plymouth County Retirement Association v. ViewRay, Inc., et al., the amended complaint alleges that we violated federal securities laws by issuing materially false and misleading statements that failed to disclose adverse facts concerning our business, operations, and financial results, and seeks damages, interest, and other relief. On August 25, 2021, the District Court dismissed the lead plaintiff’s second amended complaint, with prejudice. On September 17, 2021, the lead plaintiff filed notice of its intent to appeal the District Court’s opinion and order dismissing the complaint to the Sixth Circuit Court of Appeals. The lead plaintiff filed its opening appellate brief on January 14, 2022, and the defendants’ response is due March 15, 2022. We believe the appeal is without merit and intend to vigorously defend the litigation. Stockholder Derivative Lawsuit On July 22, 2020, a stockholder derivative lawsuit, captioned Gile derivatively on behalf of ViewRay, Inc. v. ViewRay Inc., et al., was filed against ViewRay (as a nominal defendant) and certain of its current and former officers and directors in the U.S. District Court for the Northern District of Ohio. This action alleges, purportedly on behalf of ViewRay, that the officers and directors violated Section 14(a) of the Securities Exchange Act of 1934, breached their fiduciary duties, wasted corporate assets, and were unjustly enriched based on factual assertions substantially similar to those in the class action complaint described above. The complaint seeks, among other things, damages awarded to ViewRay, restitution and disgorgement of profits in an unspecified amount, and corporate reforms. Due to the overlap between the allegations in the derivative complaint and those in the putative securities class action complaint, this lawsuit is presently stayed, pending a decision on the appeal by the Sixth Circuit Court of Appeal. Given the early stage of each of the litigation matters described above, at this time we are unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote. However, litigation is subject to inherent uncertainties, and one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect in the period in which they are resolved and on our business generally. In addition, regardless of their merits or their ultimate outcomes, lawsuits and legal proceedings are costly, divert management attention and may materially adversely affect our reputation, even if resolved in our favor. Purchase Commitments

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company derives revenue primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. Revenue is categorized as product revenue, service revenue and distribution rights revenue. The following table presents revenue disaggregated by type and geography (in thousands): Years Ended December 31, U.S. 2021 2020 2019 Product $ 31,769 $ 8,428 $ 41,985 Service 10,399 7,739 4,251 Total U.S. revenue $ 42,168 $ 16,167 $ 46,236 Outside of U.S. ("OUS") Product $ 20,096 $ 34,314 $ 37,519 Service 7,380 6,061 3,552 Distribution rights 475 475 475 Total OUS revenue $ 27,951 $ 40,850 $ 41,546 Total Product $ 51,865 $ 42,742 $ 79,504 Service 17,779 13,800 7,803 Distribution rights 475 475 475 Total revenue $ 70,119 $ 57,017 $ 87,782 Arrangements with Multiple Performance Obligations The Company frequently enters into sales arrangements that include multiple performance obligations. Such performance obligations mainly consist of (i) sale of MRIdian systems, (ii) installation of MRIdian systems, and (iii) product support, which includes extended service and maintenance. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The standalone selling price ("SSP"), is determined based on observable prices at which the Company separately sells the products and services. If a SSP is not directly observable, the Company will estimate the SSP considering market conditions or internally approved pricing guidelines related to the performance obligations. Product Revenue Product revenue is derived primarily from the sales of MRIdian system. The system contains both software and non-software components that together deliver essential functionality. Certain revenue contracts have terms that result in the control of the system transferring to the customer upon delivery and inspection, as opposed to historically upon customer acceptance. For contracts in which control of the system transfers upon delivery and inspection, the Company recognizes revenue for the systems at the point in time when delivery and inspection by the customer has occurred. For these same contracts, the Company recognizes installation revenue over the period of installation as the installation services are performed and control is transferred to the customer. For all contracts in which control continues to transfer upon post-implementation customer acceptance, revenue for the system and installation will continue to be recognized upon customer acceptance. Certain customer contracts with distributors do not require ViewRay installation at the ultimate user site, and the distributors may either perform the installation themselves or hire another party to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is shipped, which is when the control of the system is transferred to the customer. Service Revenue Service revenue is derived primarily from maintenance services. The maintenance and support service is a stand-ready obligation which is performed over the term of the arrangement and, as a result, service revenue is recognized ratably over the service period as the customers benefit from the service throughout the service period. Distribution Rights Revenue In December 2014, the Company entered into a distribution agreement with Itochu Corporation pursuant to which it appointed Itochu as its exclusive distributor for the promotion, sale and delivery of MRIdian products within Japan. In consideration of the exclusive distribution rights granted, the Company received $4.0 million, which was recorded as deferred revenue. Starting in August 2016, distribution rights revenue is recognized ratably over the remaining term of the distribution agreement of approximately 8.5 years. A time-elapsed method is used to measure progress because the control is transferred evenly over the remaining contractual period. Contract Balances The timing of revenue recognition, billings and cash collections results in short-term and long-term trade receivables, customer deposits, deferred revenues and deferred cost of revenue on the consolidated balance sheets. Trade receivables are recorded at the original invoiced amount, net of an estimated allowance for credit losses. Trade credit is generally extended on a short-term basis. The Company occasionally provides for long-term trade credit for its maintenance services so that the period between when the services are rendered to its customers and when the customers pay for that service is within one year. Thus, the Company’s trade receivables do not bear interest or contain a significant financing component. Long-term trade receivables of $5.4 million and $0.1 million were reported within other assets in the consolidated balance sheets at December 31, 2021 and 2020, respectively. These amounts are billed in accordance with the terms of the customer contracts to which they relate and are expected to be collected three Trade receivables are evaluated for expected credit losses based on past credit history of the respective customers and their current financial condition. Changes in the estimated collectability of trade receivables are included in the results of operations for the period in which the estimate is revised. Trade receivables that are deemed uncollectible are offset against the allowance for credit losses. The Company generally does not require collateral for trade receivables. There was no allowance for credit losses recorded at December 31, 2021 or 2020. Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year. Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of contract obligations and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities. Deferred cost of revenue consists of cost for inventory items that have been shipped, but revenue recognition has not yet occurred. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or the Company’s normal operating cycle. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $9.3 million, $8.3 million and $10.9 million, respectively, of revenues that were included in the deferred revenue balance at the beginning of each reporting period. Variable Consideration The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company estimates the transaction price at contract inception, including any variable consideration, and updates the estimate each reporting period for any changes. For the year ended December 31, 2019, the Company recognized $0.9 million in revenue from performance obligations satisfied in a prior period. The cumulative catch-up adjustment resulted from a change in transaction price related to variable consideration that was constrained in prior periods.

Licensing Agreement

Licensing Agreement	12 Months Ended
	Dec. 31, 2021
Licensing Agreement [Abstract]
Licensing Agreement	Licensing AgreementIn December 2004, ViewRay Technologies, Inc. entered into a licensing agreement with the University of Florida Research Foundation, Inc., or UFRF, whereby UFRF granted the Company a worldwide exclusive license to certain of UFRF’s patents in exchange for 33,652 shares of common stock and a royalty from sales of products developed and sold by the Company utilizing the licensed patents. ViewRay Technologies, Inc. met all of the product development and commercialization milestones at December 31, 2013, and started to make quarterly royalty payments in 2014. Royalty payments are based on 1% of net sales, defined as the amount collected on sales of licensed products and/or licensed processes after deducting trade and/or quantity discounts, credits on returns and allowances, outbound transportation costs paid and sales tax. Minimum quarterly royalty payments of $50 thousand commenced with the quarter ended March 31, 2014, and are payable in advance. Minimum royalties paid in any calendar year are credited against earned royalties for such calendar year. The royalty payments continue until the earlier of (i) the date that no licensed patents remain enforceable or (ii) once the payment of earned royalties cease for more than four consecutive calendar quarters. Royalty expenses based on 1% of net sales were $0.3 million, $0.7 million and $1.0 million during the years ended December 31, 2021, 2020 and 2019, respectively, and were recorded as product cost of revenue in the consolidated statements of operations and comprehensive loss. There were no minimum royalty payments in excess of 1% of net sales during the years ended December 31, 2021, 2020 and 2019.

Distribution Agreement

Distribution Agreement	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Distribution Agreement	Distribution Agreement In December 2014, the Company entered into a distribution agreement with Itochu Corporation, or Itochu, a Japanese entity, pursuant to which the Company appointed Itochu as its exclusive distributor for the sale and delivery of its MRIdian products within Japan. The exclusive distribution agreement has an initial term of 10 years from December 2014, and contains features customary in such distribution agreements. Under this distribution agreement, the Company will supply its products and services to Itochu based upon the Company’s then-current pricing. In consideration of the exclusive distribution rights granted, Itochu agreed to pay a distribution fee of $4.0 million in three installments: (i) the first installment of $1.0 million was due upon execution of the distribution agreement; (ii) the second installment of $1.0 million was due within 10 business days following submission of the application for regulatory approval of the Company’s product to the Japan regulatory authority; and (iii) the final installment of $2.0 million was due within 10 business days following receipt of approval for the Company’s product from the Japanese Ministry of Health, Labor and Welfare. The first and second installments of $2.0 million in aggregate were received in December 2014 and December 2015, respectively. In August 2016, the Company received the third and final $2.0 million installment upon the receipt of regulatory approval to market MRIdian in Japan . The entire $4.0 million distribution fee received was reclassified to deferred revenue as it was no longer refundable. In August 2016, the Company started recognizing distribution rights revenue ratably over the remaining term of the exclusive distribution agreement of approximately 8.5 years. The distribution rights revenue was $0.5 million for each of the years ended December 31, 2021, 2020 and 2019.

Equity Financing

Equity Financing	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity Financing	Equity Financing Public Offering of Common Stock On December 3, 2019, we entered into an underwriting agreement with Piper Jaffray & Co., as representatives of several underwriters (the "December 2019 Underwriters"), in connection with the issuance and sale of 47,782,500 shares of our common stock, which included the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $3.13 per share. We completed the offering on December 6, 2019 and received aggregate net proceeds of approximately $138.4 million, after deducting the underwriting discounts and commissions and offering expenses payable by us. O n January 4, 2021, the Company entered into an underwriting agreement with Piper Sandler & Co., as representative of the several underwriters named therein (the “January 2021 Underwriters”), with respect to the issuance and sale of 11,856,500 shares of our common stock, which included the full exercise of the January 2021 Underwriters’ option to purchase additional shares, at a price to the public of $4.85 per share. The Company completed the offering on January 7, 2021 and received net proceeds of approximately $53.5 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. On November 16, 2021, the Company entered into an underwriting agreement with Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (the “November 2021 Underwriters”), with respect to the issuance and sale by the Company of 14,375,000 shares of our common stock, which included the full exercise of the November 2021 Underwriters' option to purchase additional shares, at a price to the public of $5.60 per share. The Company completed the offering on November 18, 2021 , and received net proceeds of approximately $75.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. At-The-Market Offering of Common Stock In January 2019, the Company filed a registration statement with the SEC which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants, purchase contracts and/or units, including up to $100.0 million of the Company’s common shares pursuant to an at-the-market offering program with FBR, now known as B. Riley Securities. Under this at-the-market offering program, the Company did not sell any shares of its common stock during the years ended December 31, 2019 or 2020. This shelf registration statement expired in February 2022.

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Convertible Preferred Stock	Convertible Preferred StockIn March 2018, the Company issued 3,000,581 shares of Series A convertible preferred stock to an existing investor through the March 2018 Direct Registered Offering at a price of $8.31 per share. At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company’s common stock, a beneficial conversion feature of $2.7 million was recorded as a discount to the convertible preferred stock and an increase to additional paid in capital. Because the preferred stock was perpetual and convertible at the option of the holder at any time, the Company fully amortized the discount related to the beneficial conversion feature as a deemed dividend which was recognized as an increase to accumulated deficit and net loss attributable to common stockholders. Effective on April 19, 2018, all outstanding shares of Series A convertible preferred stock were converted into shares of common stock at a conversion ratio of 1 1. Further, in May 2018, the Company filed a Certificate of Elimination of the Series A Convertible Preferred Stock de-authorizing the 3,000,581 shares of Series A convertible preferred stock. The Company had no outstanding preferred stock as of December 31, 2021 and 2020.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants and Rights Note Disclosure [Abstract]
Warrants	Warrants Equity Classified Common Stock Warrants In connection with the merger of ViewRay, Inc. and ViewRay Technologies, Inc. in July 2015, or the Merger, in July and August 2015, the Company conducted a private placement offering as part of which the Company issued warrants, or the 2015 Placement Warrants, that provide the warrant holder the right to purchase 198,760 shares of common stock at an exercise price of $5.00 per share. The 2015 Placement Warrants are exercisable at any time at the option of the holder until the five-year anniversary of their date of issuance. During the year ended December 31, 2018, the Company issued 92,487 shares of its common stock upon the net exercise of 2015 Placement Warrants to purchase 159,010 shares. The remaining 39,750 shares of 2015 Placement Warrants expired in July and August 2020 and none remained outstanding at December 31, 2021. In connection with the March 2018 Direct Registered Offering, the Company issued warrants to purchase 1,418,116 shares of common stock at an exercise price of $8.31 per share. The 2018 Offering Warrants became exercisable upon issuance and expire in March 2025. None of the 2018 Offering Warrants have been exercised to date and they all remained outstanding at December 31, 2021. As separate classes of securities were issued in a bundled transaction, the gross proceeds from the March 2018 Direct Registered Offering of $59.1 million were allocated to common stock, Series A convertible preferred stock and the 2018 Offering Warrants based on their respective relative fair value upon issuance. The aggregate fair value of the 2018 Offering Warrants of $7.4 million was estimated using the Black-Scholes option-pricing model with the following assumptions: Upon Issuance Common Stock Warrants: Expected term (in years) 7.0 Expected volatility (%) 62.5% Risk-free interest rate (%) 2.8% Expected dividend yield (%) 0% The allocated proceeds from the 2018 Offering Warrants of $6.6 million was recorded in additional paid-in-capital. Liability Classified Common Stock Warrants In connection with the 2017 and 2016 Private Placements, the Company issued the 2017 and 2016 Placement Warrants, that provide the warrant holder the right to purchase 1,720,512 and 1,380,745 shares of common stock. The 2017 and 2016 Placement Warrants contain protection whereby the warrant holders will have the right to receive cash in the amount equal to the Black-Scholes value of the warrants upon the occurrence of a change in control, as defined in the agreement. The 2017 and 2016 Placement Warrants were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date, with the change in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The key terms and activity of the 2017 and 2016 Placement Warrants are summarized as follows: Issuance Date Term Exercise Price Per Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 Warrants Exercised during the Year Ended December 31, 2021 Warrants Outstanding at December 31, 2021 2017 Placement Warrants January 2017 7 years $ 3.17 — 1,618,890 118,868 1,500,022 2016 Placement Warrants August and September 2016 7 years $ 2.95 — 537,263 552 536,711 Total — 2,156,153 119,420 2,036,733 As separate classes of securities were issued in a bundled transaction, the gross proceeds of $26.1 million and $13.8 million from the 2017 and 2016 Private Placement were allocated first to the 2017 and 2016 Placement Warrants based on their fair value upon issuance, and the residuals were allocated to common stock. The fair value upon issuance of $3.4 million and $2.7 million were estimated using the Black-Scholes option-pricing model using the following assumptions: Upon Issuance 2017 Placement Warrants 2016 Placement Warrants Expected term (in years) 7.0 7.0 Expected volatility (%) 62.9% 61.6% Risk-free interest rate (%) 2.2% 1.4% Expected dividend yield (%) 0% 0% The following table summarizes the change in fair value the Company recognized related to its 2017 and 2016 Placement Warrants in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2021, 2020, and 2019: December 31, December 31, December 31, Gain (loss) on 2017 Placement Warrants $ (1,705) $ 367 $ 2,554 Gain (loss) on 2016 Placement Warrants (579) 142 (59) $ (2,284) $ 509 $ 2,496 The fair value of the 2017 and 2016 Placement Warrants at December 31, 2021 and 2020 was estimated using the Black-Scholes option-pricing model and the following weighted-average assumptions: 2017 Placement Warrants 2016 Placement Warrants December 31, December 31, December 31, December 31, Expected term (in years) 2.0 3.0 1.6 2.6 Expected volatility 86.0% 86.9% 85.5% 86.3% Risk-free interest rate 0.4% 0.2% 0.3% 0.2% Expected dividend yield 0% 0% 0% 0%

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation As of December 31, 2021, the Company had an active stock-based incentive compensation plan, an employee stock purchase plan and an equity inducement plan: the 2015 Equity Incentive Award Plan (as amended and restated, the “2015 Plan”), the 2015 Employee Stock Purchase Plan (as amended and restated, the “ESPP”), and the 2018 Equity Inducement Award Program (the “2018 Plan”), respectively. All new equity compensation grants are issued under these three plans; however, outstanding awards previously issued under inactive plans will continue to vest and remain exercisable in accordance with the terms of the respective plans. The 2015 Plan and the 2018 Plan provide for the grant of stock and stock-based awards including stock options, restricted stock units (including deferred stock units) and stock appreciation rights. Additionally, stock units may be issued as performance-based stock units to align stock compensation awards to the attainment of annual or long-term performance goals. As of December 31, 2021, there were 5.8 million shares available for grant under the 2015 Plan and 2018 Plan. Stock-Based Compensation Expense Total stock-based compensation expense recognized in the Company’s consolidated statements of operations and comprehensive loss is classified as follows (in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 1,018 $ 965 $ 2,645 Research and development 2,538 2,288 3,910 Selling and marketing 1,615 1,091 1,365 General and administrative 18,700 18,461 11,525 Total stock-based compensation expense $ 23,871 $ 22,805 $ 19,445 Our stock-based compensation expense is based on the value of the portion of share-based payment awards that are ultimately expected to vest, assuming estimated forfeitures at the time of grant. Stock-based compensation relating to stock-based awards granted to consultants was insignificant for the years ended December 31, 2021, 2020 and 2019. Restricted Stock Units, Deferred Stock Units and Performance Stock Units: The Company grants restricted stock units, deferred stock units, and performance stock units (collectively "Incentive Stock Units" or "ISUs"). Restricted Stock Units ("RSUs") are granted to the Company's board of directors and employees for their services. Deferred Stock Units ("DSUs") are granted to the Company's board of directors at their election in lieu of retainer and committee service fees. The DSUs granted to board members are either fully vested upon issuance or vest over a period of time from the grant date and will be released and settled upon termination of the board member’s services, the occurrence of a change in control event, or the tenth anniversary of the grant date. The RSUs and DSUs granted to employees and/or board members vest in equal annual or monthly installments over one In March 2021, the Company introduced a performance share plan (the “2021 PSU Plan”) as a component of its equity grants for 2021. The 2021 PSU Plan provides for the award of performance share units (“PSUs”) to employees which vest based on the achievement of performance targets related to the Company’s compound annual revenue growth rate over a three-year period. The grant date fair values of ISUs are based on the closing market price of our common stock on the grant date. Stock-based compensation expense, net of forfeitures, is recognized on a straight-line basis over the requisite service period. For PSUs, compensation expense is updated for the Company’s expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics. The weighted-average grant date fair value of ISUs granted in fiscal year 2021, 2020 and 2019 was $4.87 per share, $2.80 per share and $3.63 per share, respectively. The table below summarizes the Company's activity and related information for its ISUs: RSUs and DSUs PSUs Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2020 8,046,399 $ 3.41 — $ — Granted 2,704,909 $ 4.92 746,723 $ 4.66 Vested (4,875,305) $ 3.75 — $ — Cancelled or forfeited (339,078) $ 3.41 (39,635) $ 4.66 Unvested at December 31, 2021 5,536,925 $ 4.04 707,088 $ 4.66 Vested and unreleased 194,446 — Outstanding at December 31, 2021 5,731,371 707,088 The total grant date fair value of ISUs awarded was $16.8 million, $17.0 million and $12.2 million for the years ended December 31, 2021, 2020 and 2019, respectively. The total fair value of ISUs vested was $27.5 million, $5.1 million and $6.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. At December 31, 2021, total unrecognized stock-based compensation cost related to ISUs, net of estimated forfeitures, was $14.9 million, which is expected to be recognized over a weighted-average period of 1.7 years. As of December 31, 2021, 6.0 million shares of ISUs are expected to vest. Stock Options: Stock option awards are generally granted with an exercise price equal to the market price of our stock at the date of grant and with a four-years vesting schedule. Stock option awards generally expire 10 years from the date of grant. A summary of the Company’s stock option activity and related information is as follows: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In thousands) Options outstanding at December 31, 2020 8,142,348 $ 7.14 7.3 $ 2,638 Options granted — — Options exercised (156,199) 4.97 Options cancelled or forfeited (790,751) 9.05 Options outstanding at December 31, 2021 7,195,398 $ 6.98 6.1 $ 5,203 Options exercisable at December 31, 2021 5,958,569 $ 7.05 5.9 $ 3,847 Options vested and expected to vest at December 31, 2021 7,117,391 $ 7.00 6.1 $ 5,050 There were no options granted to employees for the year ended December 31, 2021. The weighted-average grant date fair value of options granted to employees was $1.20 and $4.67 per share for the years ended December 31, 2020 and 2019. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of options exercised was nominal for the years ended December 31, 2021, and 2020, and $7.8 million for the year ended December 31, 2019. At December 31, 2021, total unrecognized stock-based compensation cost related to stock options granted to employees, net of estimated forfeitures, was $4.3 million, which is expected to be recognized over a weighted-average period of 1.2 years. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of complex and subjective variables. The variables used to calculate the fair value of stock options using the Black-Scholes option-pricing model include actual and projected employee stock option exercise behaviors, expected price volatility of the Company’s common stock, the risk-free interest rate and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine. The risk-free interest rate is based on the zero-coupon U.S. Treasury notes, with maturities similar to the expected term of the options. The Company has not paid and does not anticipate paying cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. During the fourth quarter of 2020, the Company began to determine volatility by solely using the Company’s own historical volatility measurements, since more than four years of historical data became available in the public market. Prior to the fourth quarter of 2020, the Company determined the volatility for stock options granted based on the average historical price volatility for the Company and industry peers over a period equivalent to the expected term of the stock options grants. The forfeiture rate of stock options is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures have been estimated by the Company based upon historical and expected forfeiture experience. The fair value of employee stock options was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 Expected term (in years) 6.0 6.0 Expected volatility (%) 68.8% 60.7% Risk-free interest rate (%) 0.7% 2.4% Expected dividend yield (%) 0% 0% Employee Stock Purchase Plan: In July 2015, the Company adopted the Employee Stock Purchase Plan ("ESPP"). Certain employees, as defined by the ESPP, are eligible to participate in the ESPP if employed by the Company for at least 20 hours per week during at least five months per calendar year. Participating employees may contribute up to the lesser of 15% of their eligible earnings or $30,000 during each offering period, provided that in no event shall a participating employee be permitted to purchase more than 3,000 shares of common stock during each offering period. The purchase price of common stock purchased under the ESPP is currently equal to 85% of the lesser of the fair market value of a share of common stock on: 1) the first trading day of an offering period and 2) the last trading of each offering period. At December 31, 2021, 3.5 million shares were reserved for issuance under the ESPP, respectively. No more than 3.5 million shares of common stock may be issued under the ESPP. As of December 31, 2021, 0.3 million shares have been issued under the ESPP and 3.2 million shares remained available for future issuance under the ESPP. Purchase rights granted under the ESPP are valued using the Black-Scholes pricing model. During 2021 , the grant date for the two offering periods was April 1, 2021 and July 1, 2021. As such, the expected stock price volatility for the Company’s common stock for the ESPP purchase rights was estimated by taking the average historic price volatility of the Company industry peers based on daily price observations over a period equivalent to the expected term of the offering period. The expected term represents the period of time the ESPP purchase rights are expected to be outstanding and approximates the offering period. The latest offering period and related purchase was completed on December 31, 2021. As such, there was no unrecognized compensation cost related to the ESPP as of December 31, 2021. Total compensation expense was $0.3 million and $0.1 million for the years ended December 31, 2021 and 2020 . There was no compensation expense related to the ESPP for the year ended December 31, 2019. The fair value of each purchase right granted under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Year Ended December 31, 2021 2020 2019 Expected term (in years) 0.50 0.25 - 0.50 N/A Expected volatility (%) 84.2% - 86.0% 83.0% N/A Risk-free interest rate (%) 0.05% - 0.09% 0.09% - 0.17% N/A Expected dividend yield (%) —% —% N/A

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income Tax Expense The following reconciles the differences between income taxes computed at the federal income tax rate and the provision for income taxes: Year Ended December 31, 2021 2020 2019 Expected income tax benefit at the federal statutory rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 0.0 0.0 0.0 Change in federal statutory rate 0.0 0.0 0.0 Non-deductible stock compensation (3.1) 0.2 0.0 Non-deductible items and other (1.7) (3.6) (2.8) Federal and state credits 0.7 0.5 0.6 Change in valuation allowance (16.9) (18.1) (18.8) Total 0.0 % 0.0 % 0.0 % Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company’s net deferred tax assets consisted of the following at December 31, 2021 and 2020 (in thousands): Year Ended December 31, 2021 2020 Deferred tax assets Net operating loss carryforwards $ 140,581 $ 121,346 Research and development tax credits 9,149 6,949 Reserves and accruals 4,781 4,984 Operating lease liability 2,615 2,588 Other 6,738 4,702 Total deferred tax assets 163,864 140,569 Less: Valuation allowance (161,487) (138,214) Net deferred tax assets 2,377 2,355 Deferred tax liabilities Right-of-use assets (2,377) (2,355) Total deferred tax liabilities (2,377) (2,355) Net deferred tax assets $ — $ — The Company maintains a valuation allowance related to its deferred tax asset position when management believes it is more likely than not that the net deferred tax assets will not be realized in the future. The Company’s valuation allowance increased by $23.3 million and $21.0 million during the year ended December 31, 2021 and 2020, respectively. At December 31, 2021, the Company had federal net operating loss carryforwards of $605.5 million, which begin to expire in the year ending December 31, 2024, and $258.6 million related to state net operating loss carryforwards, which begin to expire in the year ending December 31, 2021. The Company had federal research and development tax credit carryforwards of $7.5 million, and state carryforwards of $5.0 million at the year ended December 31, 2021. The federal credits begin to expire in the year ending December 31, 2027 and the state credits carryforward indefinitely. Under the provisions of the Internal Revenue Code, or IRC, net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC. The Company performed a Section 382 analysis in February of 2022 and three ownership changes were identified, which had a corresponding limitation of tax attributes. Future owner or equity shifts could result in additional limitations on net operating loss and credit carryforwards. Because of the net operating loss and credit carryforwards, all of the Company’s federal tax returns and state returns since the year ended December 31, 2004 remain subject to federal and California examination. The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates these tax positions on an annual basis. In addition, the Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense. At December 31, 2021 and 2020, the Company’s unrecognized tax benefits consist of the following (in thousands): Year Ended December 31, 2021 2020 Unrecognized tax benefit, beginning of period $ 2,681 $ 2,158 Gross increases — current year tax positions 704 548 Gross increases — prior year tax positions — — Gross decreases — prior year tax positions (28) (25) Unrecognized tax benefit, end of period $ 3,357 $ 2,681 On March 27, 2020, the Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law. The CARES Act includes provisions relating to refundable payroll tax credits, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to the tax deprecation methods for qualified improvement property. The impact of the CARES act is estimated to be immaterial on the Company’s income tax expense.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2021
Postemployment Benefits [Abstract]
Employee Benefits	Employee BenefitsThe Company has a 401(k) Plan which covers its eligible employees. The 401(k) Plan permits the participants to defer a portion of their compensation in accordance with the provisions of Section 401(k) of the IRC. Participant contributions are limited to a maximum annual amount as set periodically by the IRC. The Company started to match 50% of eligible participant contributions up to 6% annual contribution during the year ended December 31, 2019. The Company’s matching contribution to the 401(k) Plan was $0.7 million, $1.1 million, and $0.9 million for the years ended December 31, 2021, 2020, and 2019, respectively.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Year Ended December 31, 2021 2020 2019 Net loss attributable to common stockholders, basic and diluted $ (110,048) $ (107,908) $ (120,199) Weighted-average common shares used in computing net loss per share, basic and diluted 164,521,064 147,895,561 102,001,954 Net loss per share, basic and diluted $ (0.67) $ (0.73) $ (1.18) Diluted earnings per share (“EPS”) includes the dilutive effect of common stock equivalents and is computed using the weighted-average number of common stock and common stock equivalents outstanding during the reporting period. Diluted EPS for the years ended December 31, 2021, 2020, and 2019 excluded common stock equivalents because the effect of their inclusion would be anti-dilutive or would decrease the reported loss per share. The following table sets forth securities outstanding that could potentially dilute the calculation of diluted earnings per share: Year Ended December 31, 2021 2020 2019 Options to purchase common stock 7,195,398 8,142,348 11,165,846 Warrants to purchase common stock - liability classified 2,036,733 2,156,153 2,156,153 Warrants to purchase common stock - equity classified 1,418,116 1,418,116 1,457,866 Unvested restricted stock units 6,244,013 8,046,399 4,379,777

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information The Company has one business activity, which is radiation therapy technology combined with magnetic resonance imaging, and operates in one reportable segment. The Company’s chief operating decision-maker, its chief executive officer, reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. Also, the Company does not have segment managers as the Company manages its operations as a single operating segment. The following table sets forth revenue by geographic area based on the shipping address of the customers’ location (in thousands): Year Ended December 31, 2021 2020 2019 United States $ 42,168 $ 16,167 $ 46,236 France 7,868 7,025 12,235 Taiwan 4,870 10,710 — United Kingdom 1,173 6,060 5,974 Rest of world 14,040 17,055 23,337 Total revenue $ 70,119 $ 57,017 $ 87,782 At December 31, 2021 and 2020, nearly all long-lived assets are located in the United States.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions As discussed in Note 8, the Company pays a royalty to UFRF, a stockholder in the Company, related to a licensing agreement. In November 2019, the Company entered into a distribution agreement with Chindex Shanghai International Trading Company Limited, or Chindex, which became effective in February 2020. Chindex is a subsidiary of Fosun International Limited, or Fosun. Kevin Xie, Ph.D., a member of the Company’s board of directors, was previously designated by Fosun for election to the board pursuant to a Securities Purchase Agreement related to the Company’s 2017 direct registered offering of common stock. Under the distribution agreement, Chindex will act as the Company’s distributor and regulatory agent for the sale and delivery of its MRIdian products within the People’s Republic of China, excluding Hong Kong, Macau and Taiwan. The distribution agreement has an initial term of five years with an option to renew for an additional five years. Under the distribution agreement, the Company will supply its products and services to Chindex based on an agreed upon price between the Company and Chindex. In accordance with the agreement, Chindex agreed to pay ViewRay an upfront fee, portions of which may be refundable under certain conditions, of $3.5 million, payable in three installments: (i) the first installment of $1.5 million due approximately 60 days after the effectiveness of the distribution agreement; (ii) the second installment of $1.0 million due on the first anniversary from the effective date of the agreement; and (iii) the third installment of $1.0 million due on the second anniversary from the effective date of the agreement. The Company has received the first and second installment of this payment as of December 31, 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchanges Commission (the "SEC"). The consolidated financial statements include the accounts of ViewRay, Inc. and its wholly-owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allocation of revenue to multiple performance obligations within an arrangement, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards and warrant liability, and valuation allowances against deferred tax assets. Actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company deposits its cash primarily in checking and money market accounts. The carrying amounts of the Company’s cash equivalents approximate their fair values due to their short maturities.
Restricted Cash	Restricted Cash At December 31, 2021 and 2020, the Company had an aggregate of $1.5 million of outstanding letters of credit related to its operating leases and its contractual obligations with distributors and customers. The letters of credit are collateralized by a restricted cash deposit account, which is presented as part of noncurrent assets on the balance sheets because the
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in checking and money market accounts with various financial institutions. At times, cash balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company performs periodic credit evaluations of its customers’ financial condition and generally requires deposits from its customers. The Company’s accounts receivable were derived from billings to customers. The Company’s customers representing greater than 10% of accounts receivable or revenue for the periods presented were as follows: Revenue Accounts Receivables Year Ended December 31, December 31, Customers 2021 2020 2019 2021 2020 Customer A 11 % 12 % 14 % 28 % Customer B 16 % Customer C 16 % Customer D 15 % Customer E 19 % Customer F 11 % 30 % Customer G 10 % 20 % Customer H 25 % The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of MRIdian, competition from substitute products and larger companies, protection of proprietary technology, ability to maintain distributor relationships and dependence on key individuals. Furthermore, new products to be developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. The Company relies on a concentrated number of suppliers to manufacture essentially all of the components used in MRIdian. The Company’s suppliers may encounter problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA’s Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede our ability to meet demand.
Accounts Receivables and Allowance for Doubtful Accounts	Accounts Receivables and Allowance for Credit Losses Accounts receivable are recorded at the invoiced amount, net of any allowance for credit losses, and do not bear interest. The allowance for credit losses, if any, is based on the assessment of the collectability of customer accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, restricted cash, prepaid expenses and other current assets, accounts payable, accrued liabilities, warrant liability and long-term debt. Cash equivalents are stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities current portion of long-term debt are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. The warrant liability is carried at fair value. The carrying amount of the Company’s long-term debt approximates its fair value as the stated interest rate approximates market rates currently available to the Company.
Inventory and Deposits on Purchased Inventory	Inventory and Deposits on Purchased Inventory Inventory consists of purchased components for assembling MRIdian systems and other direct and indirect costs associated with MRIdian system installation. Inventory is stated at the lower of cost or net realizable value. All inventories expected to be placed in service during the normal operating cycle of the Company for the delivery and assembly of MRIdian systems, including items expected to be on hand for more than one year, are classified as current assets. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. The Company reduces the carrying value of its inventory for the difference between cost and net realizable value and records a charge to cost of product revenues. The Company recorded an inventory lower of cost and net realizable value adjustment of $0.9 million and $0.2 million during the years ended December 31, 2021 and 2020, respectively. There was no lower of cost and net realizable value adjustment during the year ended December 31, 2019. The Company records inventory items which have been paid for but not yet received and for which title has not yet transferred to the Company as deposits on purchased inventory. Deposits on purchased inventory are included within current assets as the related inventory items are expected to be received and used in MRIdian systems within the Company’s normal operating cycle. The Company assesses the recoverability of deposits on purchased inventory based on credit assessments of the vendors and their history supplying these assets. At December 31, 2021, the Company did not have any instances whereby deposits for purchased inventory were written off or the purchased inventory was not delivered.
Shipping and Handling Costs	Shipping and Handling CostsShipping and handling costs for product shipments to customers are included in cost of product revenue. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of product revenue.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Depreciation is computed over the estimated useful lives, ranging from two Depreciation and amortization periods for property and equipment are as follows: Property and Equipment Estimated Useful Life Prototype 2 - 10 years Machinery and equipment 3 - 15 years Furniture and fixture 5 - 10 years Software 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term
Leases	Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities, current and noncurrent, on our consolidated balance sheets. We currently do not have any finance lease arrangements. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date of the lease in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include an option to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.
Asset Retirement Obligations	Asset Retirement Obligations In connection with two lease agreements and subsequent amendments, the Company has a legal obligation to remove long-lived assets constructed on the leased properties and to restore the leased properties to their original condition. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The fair value is measured based upon the present value of the expected future payments at inception and remeasured upon the extension of
Impairment of Long-Lived Assets	Impairment of Long-Lived AssetsThe Company reviews the recoverability of long-lived assets, including equipment, leasehold improvements, software and intangible assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest charge) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded.
Revenue Recognition	Revenue Recognition The Company derives revenues primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. The Company accounts for revenue contracts with customers by applying the requirements of ASC 606, Revenues from Contracts with Customers, which includes the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. In all sales arrangements, revenues are recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. For sales of MRIdian systems, beginning in the second quarter of 2019, the Company determined that the MRIdian system and installation of the MRIdian system, which had previously been one performance obligation, are now two performance obligations as they are capable of being distinct and are distinct within the context of the system contracts. This change occurred due primarily to changes in facts and circumstances, whereby there are now readily available resources outside the Company that can perform the system installations. For sales of the related support and maintenance services, a time-elapsed method is used to measure progress toward complete satisfaction of performance obligations and service revenue is recognized ratably over the service contract term, which is typically 12 months. Additional details regarding revenue recognition are included in Note 7 – Revenue .
Research and Development Costs	Research and Development Costs Expenditures, including payroll, contractor expenses and supplies, for research and development of products and manufacturing processes are expensed as incurred.
Stock-Based Compensation	Stock-Based CompensationStock-based compensation expense for all stock-based payment awards granted is based on the grant date fair value. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions (see Note 13). The fair value of the portion of the award that is ultimately expected to vest is recognized as compensation expense over the awards’ requisite service periods in the consolidated statements of operations and comprehensive loss. The Company records the value of stock-based compensation to expense straight-line over the vesting period.
Deferred Commissions	Deferred CommissionsDeferred commissions are the direct and incremental costs directly associated with the MRIdian system contracts with customers, which primarily consist of sales commissions to our direct sales force. The commissions are deferred and expensed in proportion to the revenue recognized upon the acceptance of the MRIdian system.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more-likely-than not that the deferred tax assets will not be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its net deferred tax assets. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more likely than not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. It is the Company’s policy to include any penalties and interest related to income taxes in its income tax provision; however, the Company currently has no penalties or interest related to income taxes. The earliest year that the Company is subject to examination is the year ended December 31, 2004.
Warrant Liability	Warrant Liability Certain warrants to purchase common stock provide for cash settlement in the event of a change in control, and are recorded as liabilities on the balance sheets at fair value upon issuance (see Note 12). These warrants are subject to re-measurement to fair value at each balance sheet date. Any changes in fair value are recognized in the consolidated statements of operations and comprehensive loss as other income (expense), net. Upon exercise of the warrants, the related warrant liability will be reclassified to additional paid-in capital.
Net Loss per Share	Net Loss per Share The Company’s basic net loss attributable to common stockholders per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Contingently issuable shares are included in the computation of basic net loss per share as of the date that all necessary conditions have been satisfied and issuance of the shares is no longer contingent. The diluted net loss per share is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units and warrants to purchase common stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2020-06, an update to ASC Topic 470, Subtopic - 20, Debt - Debt with Conversion and Other Options, and ASC Topic 815, Subtopic – 40, Derivatives and Hedging - Contracts in Entity's Own Equity. The ASU simplifies the guidance for certain financial instruments with characteristics of liability and equity, including convertible instruments and contracts on an entity’s own equity by reducing the number of accounting models for convertible instruments and amends guidance in ASC Topic 260, Earnings Per Share, relating to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The ASU is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2021, with early adoption permitted for fiscal years that begin after December 15, 2020. The Company does not expect significant changes to our consolidated financial statements and related notes in order to comply with ASU 2020-06. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This ASU changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This ASU was adopted as of January 1, 2021 and there were no significant changes to our consolidated financial statements and related notes.
Revenue	Product Revenue Product revenue is derived primarily from the sales of MRIdian system. The system contains both software and non-software components that together deliver essential functionality. Certain revenue contracts have terms that result in the control of the system transferring to the customer upon delivery and inspection, as opposed to historically upon customer acceptance. For contracts in which control of the system transfers upon delivery and inspection, the Company recognizes revenue for the systems at the point in time when delivery and inspection by the customer has occurred. For these same contracts, the Company recognizes installation revenue over the period of installation as the installation services are performed and control is transferred to the customer. For all contracts in which control continues to transfer upon post-implementation customer acceptance, revenue for the system and installation will continue to be recognized upon customer acceptance. Certain customer contracts with distributors do not require ViewRay installation at the ultimate user site, and the distributors may either perform the installation themselves or hire another party to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is shipped, which is when the control of the system is transferred to the customer. Service Revenue Service revenue is derived primarily from maintenance services. The maintenance and support service is a stand-ready obligation which is performed over the term of the arrangement and, as a result, service revenue is recognized ratably over the service period as the customers benefit from the service throughout the service period. Distribution Rights Revenue In December 2014, the Company entered into a distribution agreement with Itochu Corporation pursuant to which it appointed Itochu as its exclusive distributor for the promotion, sale and delivery of MRIdian products within Japan. In consideration of the exclusive distribution rights granted, the Company received $4.0 million, which was recorded as deferred revenue. Starting in August 2016, distribution rights revenue is recognized ratably over the remaining term of the distribution agreement of approximately 8.5 years. A time-elapsed method is used to measure progress because the control is transferred evenly over the remaining contractual period. Contract Balances The timing of revenue recognition, billings and cash collections results in short-term and long-term trade receivables, customer deposits, deferred revenues and deferred cost of revenue on the consolidated balance sheets. Trade receivables are recorded at the original invoiced amount, net of an estimated allowance for credit losses. Trade credit is generally extended on a short-term basis. The Company occasionally provides for long-term trade credit for its maintenance services so that the period between when the services are rendered to its customers and when the customers pay for that service is within one year. Thus, the Company’s trade receivables do not bear interest or contain a significant financing component. Long-term trade receivables of $5.4 million and $0.1 million were reported within other assets in the consolidated balance sheets at December 31, 2021 and 2020, respectively. These amounts are billed in accordance with the terms of the customer contracts to which they relate and are expected to be collected three Trade receivables are evaluated for expected credit losses based on past credit history of the respective customers and their current financial condition. Changes in the estimated collectability of trade receivables are included in the results of operations for the period in which the estimate is revised. Trade receivables that are deemed uncollectible are offset against the allowance for credit losses. The Company generally does not require collateral for trade receivables. There was no allowance for credit losses recorded at December 31, 2021 or 2020. Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year. Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of contract obligations and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities. Deferred cost of revenue consists of cost for inventory items that have been shipped, but revenue recognition has not yet occurred. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or the Company’s normal operating cycle.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Concentration of Risk	The Company’s customers representing greater than 10% of accounts receivable or revenue for the periods presented were as follows: Revenue Accounts Receivables Year Ended December 31, December 31, Customers 2021 2020 2019 2021 2020 Customer A 11 % 12 % 14 % 28 % Customer B 16 % Customer C 16 % Customer D 15 % Customer E 19 % Customer F 11 % 30 % Customer G 10 % 20 % Customer H 25 %
Schedule of Property and Equipment, Net	Depreciation and amortization periods for property and equipment are as follows: Property and Equipment Estimated Useful Life Prototype 2 - 10 years Machinery and equipment 3 - 15 years Furniture and fixture 5 - 10 years Software 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Property and equipment consisted of the following (in thousands): December 31, 2021 2020 Prototype $ 17,730 $ 17,711 Machine and equipment 17,701 17,486 Leasehold improvements 14,088 14,196 Furniture and fixtures 1,295 1,295 Software 1,389 1,389 Construction in progress 1,397 486 Property and equipment, gross 53,600 52,563 Less: accumulated depreciation and amortization (33,358) (28,501) Property and equipment, net $ 20,242 $ 24,062

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment, Net	Depreciation and amortization periods for property and equipment are as follows: Property and Equipment Estimated Useful Life Prototype 2 - 10 years Machinery and equipment 3 - 15 years Furniture and fixture 5 - 10 years Software 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Property and equipment consisted of the following (in thousands): December 31, 2021 2020 Prototype $ 17,730 $ 17,711 Machine and equipment 17,701 17,486 Leasehold improvements 14,088 14,196 Furniture and fixtures 1,295 1,295 Software 1,389 1,389 Construction in progress 1,397 486 Property and equipment, gross 53,600 52,563 Less: accumulated depreciation and amortization (33,358) (28,501) Property and equipment, net $ 20,242 $ 24,062
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued payroll and related benefits $ 17,080 $ 12,810 Accrued accounts payable $ 3,740 2,810 Payroll withholding tax, sales and other tax payable $ 1,094 1,398 Accrued legal and accounting $ 230 305 Product upgrade reserve $ 2,500 1,500 Other $ 1,911 458 Total accrued liabilities $ 26,555 $ 19,281
Schedule of Deferred Revenue	Deferred revenue consisted of the following (in thousands): December 31, 2021 2020 Deferred revenue: Product $ 1,322 $ 1,888 Services 15,385 8,857 Distribution rights 1,445 1,921 Total deferred revenue 18,152 12,666 Less: current portion of deferred revenue (13,920) (10,094) Noncurrent portion of deferred revenue $ 4,232 $ 2,572
Schedule of Other Long Term Liabilities	Other long-term liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued interest, noncurrent portion $ 704 $ 99 Asset retirement obligation 962 857 Other accrued costs 981 — Total other-long term liabilities $ 2,647 $ 956

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Liabilities	The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At December 31, 2021 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 5,030 $ 5,030 2016 Placement Warrants Liability — — 1,765 1,765 Total Warrant Liability $ — $ — $ 6,795 $ 6,795 At December 31, 2020 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 3,675 $ 3,675 2016 Placement Warrants Liability — — 1,189 1,189 Total Warrant Liability $ — $ — $ 4,864 $ 4,864
Summary of Changes in Fair Value of Level 3 Financial Liabilities	The following table summarizes the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands): Year Ended December 31, 2021 2020 2019 Fair value, beginning of period $ 4,864 $ 5,373 $ 11,844 Change in fair value of Level 3 financial liabilities 2,284 (509) (2,496) Fair value of 2016 Placement Warrants at exercise (2) — (3,457) Fair value of 2017 Placement Warrants at exercise (351) — (518) Fair value, end of period $ 6,795 $ 4,864 $ 5,373

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Scheduled Future Payments on Term Loan	The Company’s scheduled future payments on the SVB Term Loan at December 31, 2021 are as follows (in thousands): Year Ended December 31, 2022 $ 3,222 2023 19,333 2024 19,333 2025 16,112 Total future principal payments 58,000 Less: unamortized debt discount (747) Carrying value of long-term debt 57,253 Less: current portion (3,222) Long-term portion $ 54,031

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Cash Flow Transactions Arising From Lease Transactions	During the years ended December 31, 2021, 2020, and 2019, the Company recognized the following cash flow transactions arising from lease transactions (in thousands): For the Year Ended December 31, 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 2,848 $ 3,145 $ 2,451 Right-of-use assets obtained in exchange for new operating lease liabilities 1,693 643 1,647
Schedule of Future Minimum Payments and Interest Expense for Operating Leases	At December 31, 2021, the future payments and interest expense for the operating leases are as follows (in thousands): Year Ended December 31, Future Payments 2022 $ 3,264 2023 3,357 2024 3,301 2025 2,096 2026 147 Thereafter — Total undiscounted cash flows $ 12,165 Less: imputed interest (1,538) Present value of lease liabilities $ 10,627

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Disaggregated by Types and Geography	The following table presents revenue disaggregated by type and geography (in thousands): Years Ended December 31, U.S. 2021 2020 2019 Product $ 31,769 $ 8,428 $ 41,985 Service 10,399 7,739 4,251 Total U.S. revenue $ 42,168 $ 16,167 $ 46,236 Outside of U.S. ("OUS") Product $ 20,096 $ 34,314 $ 37,519 Service 7,380 6,061 3,552 Distribution rights 475 475 475 Total OUS revenue $ 27,951 $ 40,850 $ 41,546 Total Product $ 51,865 $ 42,742 $ 79,504 Service 17,779 13,800 7,803 Distribution rights 475 475 475 Total revenue $ 70,119 $ 57,017 $ 87,782

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants and Rights Note Disclosure [Abstract]
Summary of Assumptions using Black- Scholes Option Pricing Model to estimate fair value	The aggregate fair value of the 2018 Offering Warrants of $7.4 million was estimated using the Black-Scholes option-pricing model with the following assumptions: Upon Issuance Common Stock Warrants: Expected term (in years) 7.0 Expected volatility (%) 62.5% Risk-free interest rate (%) 2.8% Expected dividend yield (%) 0% Upon Issuance 2017 Placement Warrants 2016 Placement Warrants Expected term (in years) 7.0 7.0 Expected volatility (%) 62.9% 61.6% Risk-free interest rate (%) 2.2% 1.4% Expected dividend yield (%) 0% 0% The fair value of the 2017 and 2016 Placement Warrants at December 31, 2021 and 2020 was estimated using the Black-Scholes option-pricing model and the following weighted-average assumptions: 2017 Placement Warrants 2016 Placement Warrants December 31, December 31, December 31, December 31, Expected term (in years) 2.0 3.0 1.6 2.6 Expected volatility 86.0% 86.9% 85.5% 86.3% Risk-free interest rate 0.4% 0.2% 0.3% 0.2% Expected dividend yield 0% 0% 0% 0%
Schedule of Key Terms of Placement Warrants	The key terms and activity of the 2017 and 2016 Placement Warrants are summarized as follows: Issuance Date Term Exercise Price Per Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 Warrants Exercised during the Year Ended December 31, 2021 Warrants Outstanding at December 31, 2021 2017 Placement Warrants January 2017 7 years $ 3.17 — 1,618,890 118,868 1,500,022 2016 Placement Warrants August and September 2016 7 years $ 2.95 — 537,263 552 536,711 Total — 2,156,153 119,420 2,036,733 The following table summarizes the change in fair value the Company recognized related to its 2017 and 2016 Placement Warrants in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2021, 2020, and 2019: December 31, December 31, December 31, Gain (loss) on 2017 Placement Warrants $ (1,705) $ 367 $ 2,554 Gain (loss) on 2016 Placement Warrants (579) 142 (59) $ (2,284) $ 509 $ 2,496

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized in the Company’s consolidated statements of operations and comprehensive loss is classified as follows (in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 1,018 $ 965 $ 2,645 Research and development 2,538 2,288 3,910 Selling and marketing 1,615 1,091 1,365 General and administrative 18,700 18,461 11,525 Total stock-based compensation expense $ 23,871 $ 22,805 $ 19,445
Summary of RSU Activity	The table below summarizes the Company's activity and related information for its ISUs: RSUs and DSUs PSUs Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2020 8,046,399 $ 3.41 — $ — Granted 2,704,909 $ 4.92 746,723 $ 4.66 Vested (4,875,305) $ 3.75 — $ — Cancelled or forfeited (339,078) $ 3.41 (39,635) $ 4.66 Unvested at December 31, 2021 5,536,925 $ 4.04 707,088 $ 4.66 Vested and unreleased 194,446 — Outstanding at December 31, 2021 5,731,371 707,088
Summary of Company's Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In thousands) Options outstanding at December 31, 2020 8,142,348 $ 7.14 7.3 $ 2,638 Options granted — — Options exercised (156,199) 4.97 Options cancelled or forfeited (790,751) 9.05 Options outstanding at December 31, 2021 7,195,398 $ 6.98 6.1 $ 5,203 Options exercisable at December 31, 2021 5,958,569 $ 7.05 5.9 $ 3,847 Options vested and expected to vest at December 31, 2021 7,117,391 $ 7.00 6.1 $ 5,050
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date	The fair value of employee stock options was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2020 2019 Expected term (in years) 6.0 6.0 Expected volatility (%) 68.8% 60.7% Risk-free interest rate (%) 0.7% 2.4% Expected dividend yield (%) 0% 0%
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Purchases at Grant Date	The fair value of each purchase right granted under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Year Ended December 31, 2021 2020 2019 Expected term (in years) 0.50 0.25 - 0.50 N/A Expected volatility (%) 84.2% - 86.0% 83.0% N/A Risk-free interest rate (%) 0.05% - 0.09% 0.09% - 0.17% N/A Expected dividend yield (%) —% —% N/A

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Differences Between Federal Income Tax Rate and Effective Tax Rate	The following reconciles the differences between income taxes computed at the federal income tax rate and the provision for income taxes: Year Ended December 31, 2021 2020 2019 Expected income tax benefit at the federal statutory rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 0.0 0.0 0.0 Change in federal statutory rate 0.0 0.0 0.0 Non-deductible stock compensation (3.1) 0.2 0.0 Non-deductible items and other (1.7) (3.6) (2.8) Federal and state credits 0.7 0.5 0.6 Change in valuation allowance (16.9) (18.1) (18.8) Total 0.0 % 0.0 % 0.0 %
Schedule of Deferred Tax Assets	The principal components of the Company’s net deferred tax assets consisted of the following at December 31, 2021 and 2020 (in thousands): Year Ended December 31, 2021 2020 Deferred tax assets Net operating loss carryforwards $ 140,581 $ 121,346 Research and development tax credits 9,149 6,949 Reserves and accruals 4,781 4,984 Operating lease liability 2,615 2,588 Other 6,738 4,702 Total deferred tax assets 163,864 140,569 Less: Valuation allowance (161,487) (138,214) Net deferred tax assets 2,377 2,355 Deferred tax liabilities Right-of-use assets (2,377) (2,355) Total deferred tax liabilities (2,377) (2,355) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits	At December 31, 2021 and 2020, the Company’s unrecognized tax benefits consist of the following (in thousands): Year Ended December 31, 2021 2020 Unrecognized tax benefit, beginning of period $ 2,681 $ 2,158 Gross increases — current year tax positions 704 548 Gross increases — prior year tax positions — — Gross decreases — prior year tax positions (28) (25) Unrecognized tax benefit, end of period $ 3,357 $ 2,681

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Computation of Company's Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Year Ended December 31, 2021 2020 2019 Net loss attributable to common stockholders, basic and diluted $ (110,048) $ (107,908) $ (120,199) Weighted-average common shares used in computing net loss per share, basic and diluted 164,521,064 147,895,561 102,001,954 Net loss per share, basic and diluted $ (0.67) $ (0.73) $ (1.18)
Dilutive Securities Excluded from Calculation of Diluted Earnings Per Share	The following table sets forth securities outstanding that could potentially dilute the calculation of diluted earnings per share: Year Ended December 31, 2021 2020 2019 Options to purchase common stock 7,195,398 8,142,348 11,165,846 Warrants to purchase common stock - liability classified 2,036,733 2,156,153 2,156,153 Warrants to purchase common stock - equity classified 1,418,116 1,418,116 1,457,866 Unvested restricted stock units 6,244,013 8,046,399 4,379,777

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of Revenue by Geographic Area Based on the Shipping Address of the Customers' Location	The following table sets forth revenue by geographic area based on the shipping address of the customers’ location (in thousands): Year Ended December 31, 2021 2020 2019 United States $ 42,168 $ 16,167 $ 46,236 France 7,868 7,025 12,235 Taiwan 4,870 10,710 — United Kingdom 1,173 6,060 5,974 Rest of world 14,040 17,055 23,337 Total revenue $ 70,119 $ 57,017 $ 87,782

Background and Organization - A

Background and Organization - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (110,048)	$ (107,908)	$ (120,199)
Net cash used in operations	(62,091)	(63,474)	$ (79,567)
Cash and cash equivalents	$ 218,348	$ 156,720

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Significant Accounting Policies [Line Items]
Restricted cash	$ 1,460,000	$ 1,460,000
Letters of credit drawn, amount	0	0
Allowance for doubtful accounts	0	0
Inventory lower of cost and net realizable value adjustment	883,000	150,000	$ 0
Asset retirement obligation	1,000,000
Impairment loss recognized	$ 0	0	0
Service contract term (in months)	12 months
Capitalized costs associated with development of software	$ 0
Deferred commission	3,300,000	2,400,000
Asset Retirement Obligation
Significant Accounting Policies [Line Items]
Accretion expenses	$ 105,000	$ 63,000	$ 43,000
Software
Significant Accounting Policies [Line Items]
Property and equipment, useful life (in years)	3 years
Minimum
Significant Accounting Policies [Line Items]
Property and equipment, useful life (in years)	2 years
Maximum
Significant Accounting Policies [Line Items]
Property and equipment, useful life (in years)	15 years
Collateral for Letters of Credit
Significant Accounting Policies [Line Items]
Restricted cash	$ 1,500,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Customers Representing Greater than 10% of Accounts Receivable and Revenue (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue | Customer A
Concentration Risk [Line Items]
Percentage of concentration risk	11.00%	12.00%	14.00%
Revenue | Customer E
Concentration Risk [Line Items]
Percentage of concentration risk		19.00%
Revenue | Customer F
Concentration Risk [Line Items]
Percentage of concentration risk		11.00%
Revenue | Customer G
Concentration Risk [Line Items]
Percentage of concentration risk		10.00%
Accounts Receivables | Customer A
Concentration Risk [Line Items]
Percentage of concentration risk	28.00%
Accounts Receivables | Customer B
Concentration Risk [Line Items]
Percentage of concentration risk	16.00%
Accounts Receivables | Customer C
Concentration Risk [Line Items]
Percentage of concentration risk	16.00%
Accounts Receivables | Customer D
Concentration Risk [Line Items]
Percentage of concentration risk	15.00%
Accounts Receivables | Customer F
Concentration Risk [Line Items]
Percentage of concentration risk		30.00%
Accounts Receivables | Customer G
Concentration Risk [Line Items]
Percentage of concentration risk		20.00%
Accounts Receivables | Customer H
Concentration Risk [Line Items]
Percentage of concentration risk		25.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization Periods for Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Minimum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	2 years
Maximum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	15 years
Prototype | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	2 years
Prototype | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	10 years
Machinery and equipment | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	3 years
Machinery and equipment | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	15 years
Furniture and fixture | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	5 years
Furniture and fixture | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	10 years
Software
Property Plant And Equipment [Line Items]
Property and equipment, useful life (in years)	3 years

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 53,600	$ 52,563
Less: accumulated depreciation and amortization	(33,358)	(28,501)
Property and equipment, net	20,242	24,062
Prototype
Property Plant And Equipment [Line Items]
Property and equipment, gross	17,730	17,711
Machine and equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	17,701	17,486
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	14,088	14,196
Furniture and fixture
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,295	1,295
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,389	1,389
Construction in progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,397	$ 486

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Depreciation and amortization	$ 6	$ 6.4	$ 4.7

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Accrued payroll and related benefits	$ 17,080	$ 12,810
Accrued accounts payable	3,740	2,810
Payroll withholding tax, sales and other tax payable	1,094	1,398
Accrued legal and accounting	230	305
Product upgrade reserve	2,500	1,500
Other	1,911	458
Total accrued liabilities	$ 26,555	$ 19,281

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Revenue [Line Items]
Total deferred revenue	$ 18,152	$ 12,666
Less: current portion of deferred revenue	(13,920)	(10,094)
Noncurrent portion of deferred revenue	4,232	2,572
Product
Deferred Revenue [Line Items]
Total deferred revenue	1,322	1,888
Service
Deferred Revenue [Line Items]
Total deferred revenue	15,385	8,857
Distribution rights
Deferred Revenue [Line Items]
Total deferred revenue	$ 1,445	$ 1,921

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Other Long Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Accrued interest, noncurrent portion	$ 704	$ 99
Asset retirement obligation	962	857
Other accrued costs	981	0
Total other-long term liabilities	$ 2,647	$ 956

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Warrants exercised (in shares)	119,420	0
Change in fair value of Level 3 financial liabilities	$ 2,284	$ (509)	$ (2,496)
2016 and 2017 Private Placement Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Warrants exercised (in shares)		0
Aggregate fair value of warrants upon exercise	400
Change in fair value of Level 3 financial liabilities	$ 2,300	$ (500)	$ (2,500)

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value of Financial Liabilities (Details) - Fair Value Measurement on Recurring Basis - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	$ 6,795	$ 4,864
2017 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	5,030	3,675
2016 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	1,765	1,189
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 1 | 2017 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 1 | 2016 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2 | 2017 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2 | 2016 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	6,795	4,864
Level 3 | 2017 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	5,030	3,675
Level 3 | 2016 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	$ 1,765	$ 1,189

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning of period	$ 4,864	$ 5,373	$ 11,844
Change in fair value of Level 3 financial liabilities	2,284	(509)	(2,496)
Fair value, end of period	6,795	4,864	5,373
2016 Placement Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value of Placement Warrants at exercise	(2)	0	(3,457)
2017 Placement Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value of Placement Warrants at exercise	$ (351)	$ 0	$ (518)

Debt - Additional Information (

Debt - Additional Information (Details)	Oct. 30, 2021	Oct. 29, 2021	Oct. 30, 2020USD ($)installment	Oct. 29, 2020USD ($)	Dec. 30, 2019	Dec. 31, 2018USD ($)installment	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018USD ($)
SVB Term Loan
Debt Instrument [Line Items]
Total principal amount			$ 58,000,000	$ 56,000,000		$ 56,000,000			$ 56,000,000
Debt instrument interest rate percentage				6.30%		6.30%			6.30%
Length of revenue (in months)								12 months	12 months
Number of installments | installment			36			36
Number of installments if achieving trailing revenue target and company so elects | installment						30
Final payment percentage of original principal amount			3.70%	3.15%		3.15%			3.15%
Proceeds from term loan									$ 55,400,000
Legal and consulting fees									600,000
Revenue cushion (as a percent)								25.00%
Annual growth covenant (as a percent)								10.00%
Debt instrument minimum liquidity ratio financial covenant		170.00%	170.00%	175.00%	150.00%		175.00%
Debt instrument prepayment premium (as a percent)			3.00%	2.00%	1.00%		2.00%
Minimum trailing period for revenue thresholds under minimum revenue financial covenant (in months)			12 months
Debt instrument final payment			$ 800,000
SVB Term Loan | Minimum
Debt Instrument [Line Items]
Debt instrument prepayment premium (as a percent)	2.00%	300.00%
SVB Term Loan | Maximum
Debt Instrument [Line Items]
Debt instrument minimum liquidity ratio financial covenant		135.00%
Debt instrument prepayment premium (as a percent)	2.50%	3.50%
SVB Term Loan | Prime Rate
Debt Instrument [Line Items]
Debt instrument floating rate (as a percent)			2.40%
CRG Term Loan
Debt Instrument [Line Items]
Debt extinguishment loss									2,400,000
Write-off of unamortized debt discount and debt issuance costs									$ 300,000

Debt - Scheduled Future Payment

Debt - Scheduled Future Payments on Term Loan (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Less: current portion	$ (3,222)	$ 0
Long-term portion	54,031	$ 56,940
SVB Term Loan
Debt Instrument [Line Items]
2022	3,222
2023	19,333
2024	19,333
2025	16,112
Total future principal payments	58,000
Less: unamortized debt discount	(747)
Carrying value of long-term debt	57,253
Less: current portion	(3,222)
Long-term portion	$ 54,031

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Operating Leased Assets [Line Items]
Weighted-average remaining lease term (in years)	4 years
Weighted-average discount rate (as a percent)	7.60%
Operating lease cost | $	$ 2.8	$ 3.1	$ 2.9
Rent expense | $			$ 1.4
Purchase commitments | $	$ 6.4
Lease Agreement | Oakwood Village, Ohio
Operating Leased Assets [Line Items]
Area of rentable space (in square feet)	19,800
Lease Agreement | Mountain View, California
Operating Leased Assets [Line Items]
Area of rentable space (in square feet)	25,500
Lease Agreement | Mountain View, California | Maximum
Operating Leased Assets [Line Items]
Lease agreement, renewal term (in years)	5 years
Lease Agreement | Mountain View, California
Operating Leased Assets [Line Items]
Area of rentable space (in square feet)	24,600
Sub-Lease Agreement | Denver, Colorado
Operating Leased Assets [Line Items]
Area of rentable space (in square feet)	12,800

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Cash Flow Transactions Arising From Lease Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 2,848	$ 3,145	$ 2,451
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,693	$ 643	$ 1,647

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments and Interest Expense for Operating Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 3,264
2023	3,357
2024	3,301
2025	2,096
2026	147
Thereafter	0
Total undiscounted cash flows	12,165
Less: imputed interest	(1,538)
Present value of lease liabilities	$ 10,627

Revenue - Summary of Revenue Di

Revenue - Summary of Revenue Disaggregated by Types and Geography (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Total revenue	$ 70,119	$ 57,017	$ 87,782
Product
Disaggregation Of Revenue [Line Items]
Total revenue	51,865	42,742	79,504
Service
Disaggregation Of Revenue [Line Items]
Total revenue	17,779	13,800	7,803
Distribution rights
Disaggregation Of Revenue [Line Items]
Total revenue	475	475	475
U.S.
Disaggregation Of Revenue [Line Items]
Total revenue	42,168	16,167	46,236
U.S. | Product
Disaggregation Of Revenue [Line Items]
Total revenue	31,769	8,428	41,985
U.S. | Service
Disaggregation Of Revenue [Line Items]
Total revenue	10,399	7,739	4,251
Outside of U.S. ("OUS")
Disaggregation Of Revenue [Line Items]
Total revenue	27,951	40,850	41,546
Outside of U.S. ("OUS") | Product
Disaggregation Of Revenue [Line Items]
Total revenue	20,096	34,314	37,519
Outside of U.S. ("OUS") | Service
Disaggregation Of Revenue [Line Items]
Total revenue	7,380	6,061	3,552
Outside of U.S. ("OUS") | Distribution rights
Disaggregation Of Revenue [Line Items]
Total revenue	$ 475	$ 475	$ 475

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2014
Revenues [Line Items]
Long-term trade credit maintenance services term (in years)		1 year
Long-term trade receivables		$ 5,400,000	$ 100,000
Allowance for doubtful accounts		0	0
Deferred revenue, recognized		$ 9,300,000	$ 8,300,000	$ 10,900,000
Company recognized revenue from performance obligations satisfied in a prior period				$ 900,000
Minimum
Revenues [Line Items]
Expected long-term trade receivables collection period (in years)		3 years
Maximum
Revenues [Line Items]
Expected long-term trade receivables collection period (in years)		4 years
Itochu Corporation Agreement
Revenues [Line Items]
Remaining term of distribution agreement (in years)	8 years 6 months
Itochu Corporation Agreement | Distribution Rights
Revenues [Line Items]
Distribution revenue reclassified as deferred revenue					$ 4,000,000
Remaining term of distribution agreement (in years)	8 years 6 months

Licensing Agreement- Additional

Licensing Agreement- Additional Information (Details) - Licensing Agreements - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2004	Mar. 31, 2014	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2014
Licenses Agreements [Line Items]
Common Stock granted in exchange for licensing (in shares)	33,652
Percentage of royalty payment based on net sale (as a percent)			1.00%	1.00%	1.00%	1.00%
Royalty Expense			$ 0	$ 0	$ 0
Cost of Sales
Licenses Agreements [Line Items]
Royalty Expense			$ 300,000	$ 700,000	$ 1,000,000
Minimum
Licenses Agreements [Line Items]
Royalty payment per quarter		$ 50,000

Distribution Agreement - Additi

Distribution Agreement - Additional Information (Details) - Itochu Corporation Agreement $ in Millions	1 Months Ended		12 Months Ended			24 Months Ended
	Aug. 31, 2016USD ($)	Dec. 31, 2014USD ($)installment	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2015USD ($)
Distribution Agreement [Line Items]
Distribution agreement term (in years)		10 years
Distribution fees			$ 0.5	$ 0.5	$ 0.5
Number of installments | installment		3
Remaining term of distribution agreement (in years)	8 years 6 months
Distribution rights
Distribution Agreement [Line Items]
Distribution fees		$ 4
Payment period		10 days
Distribution fee reclassified to deferred revenue	$ 4
Distribution rights | First Installment
Distribution Agreement [Line Items]
Distribution fees		$ 1
Distribution rights | Second Installment
Distribution Agreement [Line Items]
Distribution fees		1
Distribution rights | Third Installment
Distribution Agreement [Line Items]
Distribution fees		$ 2
Distribution fees payment	$ 2
Distribution rights | First and Second Installment
Distribution Agreement [Line Items]
Distribution fees payment						$ 2

Equity Financing (Details)

Equity Financing (Details) - USD ($)	Nov. 18, 2021	Nov. 16, 2021	Jan. 07, 2021	Jan. 04, 2021	Dec. 06, 2019	Dec. 03, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 31, 2019
Subsidiary Sale Of Stock [Line Items]
Aggregate proceeds from issuance of common stock							$ 137,884,000	$ 0	$ 149,559,000
Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares issued in transaction		14,375,000		11,856,500		47,782,500
Sale of stock, price (in dollars per share)		$ 5.60		$ 4.85		$ 3.13
Aggregate proceeds from issuance of common stock	$ 75,100,000		$ 53,500,000		$ 138,400,000
Stock issued during period							26,231,500		47,782,500
At The Market Offering Program January 2019 | Maximum
Subsidiary Sale Of Stock [Line Items]
Maximum common stock saleable shares, value										$ 100,000,000
Maximum aggregate offering price										$ 250,000,000
At The Market Offering Program January 2019 | Common Stock
Subsidiary Sale Of Stock [Line Items]
Stock issued during period								0	0

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 19, 2018	May 31, 2018	Mar. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Convertible Preferred Stock [Line Items]
Preferred stock conversion rate	100.00%
Convertible preferred stock, shares outstanding				0	0
Series A Convertible Preferred Stock | 2018 Direct Registered Offering
Convertible Preferred Stock [Line Items]
Stock issued during period			3,000,581
Stock price (in dollars per share)			$ 8.31
Convertible preferred stock, beneficial conversion feature			$ 2.7
Conversion of Stock, Shares Converted	3,000,581
De-Authorized Series A Convertible Preferred Stock | 2018 Direct Registered Offering
Convertible Preferred Stock [Line Items]
Conversion of Stock, Shares Converted		3,000,581

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended				3 Months Ended	12 Months Ended
	Jan. 31, 2017	Sep. 30, 2016	Aug. 31, 2015	Jul. 31, 2015	Mar. 31, 2018	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2020
Common Stock Warrants [Line Items]
Placement warrants not exercised and remained outstanding (in shares)						2,036,733		2,156,153
Proceed from private placement and equity issuances, gross	$ 26.1	$ 13.8
Fair value of warrants upon issuance	$ 3.4	$ 2.7
2018 Direct Registered Offering | Common Stock
Common Stock Warrants [Line Items]
Warrants issued (in shares)					1,418,116
Warrant exercise price (in dollars per share)					$ 8.31
Number of warrant exercised (in shares)						0
Proceed from private placement and equity issuances, gross					$ 59.1
Fair value of warrants upon issuance					7.4
Allocated portion of proceeds from issuance of stock and warrants recorded in additional paid-in-capital					$ 6.6
2015 Placement Warrants
Common Stock Warrants [Line Items]
Warrants issued (in shares)			198,760	198,760
Warrant exercise price (in dollars per share)			$ 5	$ 5
Common stock warrants, expiry term (in years)			5 years	5 years
Shares issued from stock warrant exercises (in shares)							92,487
Number of warrant exercised (in shares)							159,010
Number of warrant expired (in shares)			39,750	39,750
Placement warrants not exercised and remained outstanding (in shares)						0
2016 Placement Warrants Liability
Common Stock Warrants [Line Items]
Warrants issued (in shares)		1,380,745
Warrant exercise price (in dollars per share)						$ 2.95
Placement warrants not exercised and remained outstanding (in shares)						536,711		537,263
2017 Placement Warrants Liability
Common Stock Warrants [Line Items]
Warrants issued (in shares)	1,720,512
Warrant exercise price (in dollars per share)						$ 3.17
Placement warrants not exercised and remained outstanding (in shares)						1,500,022		1,618,890

Warrants - Summary of Assumptio

Warrants - Summary of Assumptions to Use Option Pricing Model (Details)	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2018	Jan. 31, 2017	Sep. 30, 2016
2018 Direct Registered Offering | Expected term (in years)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs			7
2018 Direct Registered Offering | Expected volatility (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs			0.625
2018 Direct Registered Offering | Risk-free interest rate (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs			0.028
2018 Direct Registered Offering | Expected dividend yield (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs			0
2017 Placement Warrants Liability | Expected term (in years)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	2	3		7
2017 Placement Warrants Liability | Expected volatility (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.860	0.869		0.629
2017 Placement Warrants Liability | Risk-free interest rate (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.004	0.002		0.022
2017 Placement Warrants Liability | Expected dividend yield (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0	0		0
2016 Placement Warrants Liability | Expected term (in years)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	1.6	2.6			7
2016 Placement Warrants Liability | Expected volatility (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.855	0.863			0.616
2016 Placement Warrants Liability | Risk-free interest rate (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.003	0.002			0.014
2016 Placement Warrants Liability | Expected dividend yield (%)
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0	0			0

Warrants - Schedule of Key Term

Warrants - Schedule of Key Terms of Placement Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants exercised (in shares)	119,420	0
Warrants outstanding (in shares)	2,036,733	2,156,153
2017 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Term	7 years
Exercise price (USD per share)	$ 3.17
Warrants exercised (in shares)	118,868	0
Warrants outstanding (in shares)	1,500,022	1,618,890
2016 Placement Warrants Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Term	7 years
Exercise price (USD per share)	$ 2.95
Warrants exercised (in shares)	552	0
Warrants outstanding (in shares)	536,711	537,263

Warrants Schedule of Gain (Loss

Warrants Schedule of Gain (Loss) on Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Common Stock Warrants [Line Items]
Change in fair value of warrant liability	$ (2,284,000)	$ 509,000	$ 2,496,000
2017 Placement Warrants Liability
Schedule Of Common Stock Warrants [Line Items]
Change in fair value of warrant liability	(1,705,000)	367,000	2,554,000
2016 Placement Warrants Liability
Schedule Of Common Stock Warrants [Line Items]
Change in fair value of warrant liability	$ (579,000)	$ 142,000	$ (59,000)

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021USD ($)offeringPeriodhourplan$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of plans | plan		3
Vesting period (in years)		4 years
Weighted average period for recognition of compensation costs (in years)		1 year 2 months 12 days
Expiration period of stock option plan (in years)		10 years
Options granted (in shares) | shares		0
Weighted average grant date fair value of options granted, per share (in dollars per share) | $ / shares			$ 1.20	$ 4.67
Aggregate intrinsic value of options exercised				$ 7,800,000
Unrecognized compensation cost		$ 4,300,000
Stock-based compensation expense		$ 23,871,000	$ 22,805,000	$ 19,445,000
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value of RSUs granted (in dollars per share) | $ / shares		$ 4.87	$ 2.80	$ 3.63
Total grant date fair value of RSUs		$ 16,800,000	$ 17,000,000	$ 12,200,000
Total fair value of RSUs vested		27,500,000	5,100,000	6,400,000
Unrecognized stock based compensation cost		$ 14,900,000
Weighted average period for recognition of compensation costs (in years)		1 year 8 months 12 days
Shares expected to vest (in shares) | shares		6,000,000
Restricted Stock Units (RSUs) | Employees | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (in years)		3 years
Restricted Stock Units (RSUs) | Employees | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (in years)		1 year
Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum hours worked per week | hour		20
Minimum months worked (in months)		5 months
2015 and 2018 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant (in shares) | shares		5,800,000
2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum contribution percentage amount of employee's base compensation (as a percent)		15.00%
Maximum employee contribution in to share purchase plan per offering		$ 30,000
Number of common stock authorized for issuance (in shares) | shares		3,000
Percentage of market value price of common stock under Employee Stock Purchase Plan (as a percent)		85.00%
Common stock reserved for issuance (in shares) | shares		3,500,000
Shares issued under ESPP (in shares) | shares		300,000
Common stock remained available for issuance pursuant to the purchase plan (in shares) | shares		3,200,000
Number of offering periods | offeringPeriod		2
Stock-based compensation expense		$ 300,000	$ 100,000	$ 0
2015 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock authorized for issuance (in shares) | shares		3,500,000
2015 Employee Stock Purchase Plan | Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock based compensation cost		$ 0
Two Thousand and Twenty One Performance Share Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period (in years)	3 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 23,871	$ 22,805	$ 19,445
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,018	965	2,645
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,538	2,288	3,910
Selling and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,615	1,091	1,365
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 18,700	$ 18,461	$ 11,525

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
RSUs and DSUs
Number of Shares
Unvested beginning balance (in shares)	8,046,399
Granted (in shares)	2,704,909
Vested (in shares)	(4,875,305)
Cancelled or forfeited (in shares)	(339,078)
Unvested ending balance (in shares)	5,536,925
Vested and unreleased (in shares)	194,446
Outstanding at end of period (in shares)	5,731,371
Weighted Average Grant Date Fair Value
Unvested at beginning of period (in dollars per share) | $ / shares	$ 3.41
Granted (in dollars per share) | $ / shares	4.92
Vested (in dollars per share) | $ / shares	3.75
Cancelled or forfeited (in dollars per share) | $ / shares	3.41
Unvested at end of period (in dollars per share) | $ / shares	$ 4.04
PSUs
Number of Shares
Unvested beginning balance (in shares)	0
Granted (in shares)	746,723
Vested (in shares)	0
Cancelled or forfeited (in shares)	(39,635)
Unvested ending balance (in shares)	707,088
Vested and unreleased (in shares)	0
Outstanding at end of period (in shares)	707,088
Weighted Average Grant Date Fair Value
Unvested at beginning of period (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	4.66
Vested (in dollars per share) | $ / shares	0
Cancelled or forfeited (in dollars per share) | $ / shares	4.66
Unvested at end of period (in dollars per share) | $ / shares	$ 4.66

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Company's Stock Option Activity and Related Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Stock Options Outstanding
Beginning balance (in shares)	8,142,348
Options granted (in shares)	0
Options exercised (in shares)	(156,199)
Options cancelled or forfeited (in shares)	(790,751)
Ending balance (in shares)	7,195,398	8,142,348
Options exercisable (in shares)	5,958,569
Options vested and expected to vest (in shares)	7,117,391
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 7.14
Options granted (in dollars per share)	0
Options exercised (in dollars per share)	4.97
Options cancelled or forfeited (in dollars per share)	9.05
Ending balance (in dollars per share)	6.98	$ 7.14
Options exercisable (in dollars per share)	7.05
Options vested and expected to vest (in dollars per share)	$ 7
Weighted- Average Remaining Contractual Life (Years)
Options Outstanding (in years)	6 years 1 month 6 days	7 years 3 months 18 days
Options exercisable (in years)	5 years 10 months 24 days
Options vested and expected to vest (in years)	6 years 1 month 6 days
Aggregate Intrinsic Value
Options outstanding	$ 5,203	$ 2,638
Options exercisable	3,847
Options vested and expected to vest	$ 5,050

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options/Purchases at Grant Date (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years	6 years
Expected volatility (%)	68.80%	60.70%
Risk-free interest rate (%)	0.70%	2.40%
Expected dividend yield (%)	0.00%	0.00%
2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months
Expected volatility (%)		83.00%
Expected dividend yield (%)	0.00%	0.00%
Risk-free interest rate (%), Minimum	0.05%	0.09%
Risk-free interest rate (%), Maximum	0.09%	0.17%
2015 Employee Stock Purchase Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	3 months
Expected volatility (%)	84.20%
2015 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months
Expected volatility (%)	86.00%

Income Taxes - Income Tax Recon

Income Taxes - Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Expected income tax benefit at the federal statutory rate	21.00%	21.00%	21.00%
State taxes, net of federal benefit	0.00%	0.00%	0.00%
Change in federal statutory rate	0.00%	0.00%	0.00%
Non-deductible stock compensation	(3.10%)	0.20%	0.00%
Non-deductible items and other	(1.70%)	(3.60%)	(2.80%)
Federal and state credits	0.70%	0.50%	0.60%
Change in valuation allowance	(16.90%)	(18.10%)	(18.80%)
Total	(0.00%)	0.00%	0.00%

Income Taxes - Deferred Income

Income Taxes - Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets
Net operating loss carryforwards	$ 140,581	$ 121,346
Research and development tax credits	9,149	6,949
Reserves and accruals	4,781	4,984
Operating lease liability	2,615	2,588
Other	6,738	4,702
Total deferred tax assets	163,864	140,569
Less: Valuation allowance	(161,487)	(138,214)
Net deferred tax assets	2,377	2,355
Deferred tax liabilities
Right-of-use assets	(2,377)	(2,355)
Total deferred tax liabilities	(2,377)	(2,355)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) $ in Millions	1 Months Ended	12 Months Ended
	Feb. 28, 2022Installment	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Income Taxes [Line Items]
Deferred tax valuation allowance increase (decrease)		$ 23.3	$ 21
Forecast | Subsequent Event
Income Taxes [Line Items]
Number of ownership changes | Installment	3
Federal
Income Taxes [Line Items]
Net operating loss carryforwards		605.5
Federal | Research Tax Credit Carryforward
Income Taxes [Line Items]
Tax credit carryforwards		7.5
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating loss carryforwards		258.6
State and Local Jurisdiction | Research Tax Credit Carryforward
Income Taxes [Line Items]
Tax credit carryforwards		$ 5

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefit, beginning of period	$ 2,681	$ 2,158
Gross increases — current year tax positions	704	548
Gross increases — prior year tax positions	0	0
Gross decreases — prior year tax positions	(28)	(25)
Unrecognized tax benefit, end of period	$ 3,357	$ 2,681

Employee Benefits - Additional

Employee Benefits - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution (as a percent)	50.00%
Matching contribution to 401(k) plan	$ 0.7	$ 1.1	$ 0.9
Maximum
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution percent of eligible compensation (as a percent)	6.00%

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Company's Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss attributable to common stockholders, basic	$ (110,048)	$ (107,908)	$ (120,199)
Net loss attributable to common stockholders, diluted	$ (110,048)	$ (107,908)	$ (120,199)
Weighted-average common shares used in computing net loss per share, basic (in shares)	164,521,064	147,895,561	102,001,954
Weighted-average common shares used in computing net loss per share, diluted (in shares)	164,521,064	147,895,561	102,001,954
Net loss per share, basic (USD per share)	$ (0.67)	$ (0.73)	$ (1.18)
Net loss per share, diluted (USD per share)	$ (0.67)	$ (0.73)	$ (1.18)

Net Loss Per Share - Dilutive S

Net Loss Per Share - Dilutive Securities Excluded from Calculation of Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities excluded from calculation of diluted earnings per share	7,195,398	8,142,348	11,165,846
Warrants to purchase common stock - liability classified
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities excluded from calculation of diluted earnings per share	2,036,733	2,156,153	2,156,153
Warrants to purchase common stock - equity classified
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities excluded from calculation of diluted earnings per share	1,418,116	1,418,116	1,457,866
Unvested restricted stock units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities excluded from calculation of diluted earnings per share	6,244,013	8,046,399	4,379,777

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	1

Segment and Geographic Inform_4

Segment and Geographic Information - Summary of Revenue by Geographic Area Based on the Shipping Address of the Customers' Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Entity Wide Revenue Major Customer [Line Items]
Total revenue	$ 70,119	$ 57,017	$ 87,782
United States
Entity Wide Revenue Major Customer [Line Items]
Total revenue	42,168	16,167	46,236
France
Entity Wide Revenue Major Customer [Line Items]
Total revenue	7,868	7,025	12,235
Taiwan
Entity Wide Revenue Major Customer [Line Items]
Total revenue	4,870	10,710	0
United Kingdom
Entity Wide Revenue Major Customer [Line Items]
Total revenue	1,173	6,060	5,974
Rest of world
Entity Wide Revenue Major Customer [Line Items]
Total revenue	$ 14,040	$ 17,055	$ 23,337

Related Party Transactions (Det

Related Party Transactions (Details) - Chindex Shanghai International Trading Company Limited $ in Millions	Nov. 29, 2019USD ($)installment
Related Party Transaction [Line Items]
Distribution agreement term (in years)	5 years
Distribution agreement additional term (in years)	5 years
Number of installments | installment	3
Upfront Fees
Related Party Transaction [Line Items]
Distribution fees	$ 3.5
Upfront Fees | First Installment
Related Party Transaction [Line Items]
Distribution fees	$ 1.5
Installment period (in days)	60 days
Upfront Fees | Second Installment
Related Party Transaction [Line Items]
Distribution fees	$ 1
Upfront Fees | Third Installment
Related Party Transaction [Line Items]
Distribution fees	$ 1